WO2022212576A1 - Compositions and methods for delivery of rna - Google Patents

Compositions and methods for delivery of rna Download PDF

Info

Publication number
WO2022212576A1
WO2022212576A1 PCT/US2022/022642 US2022022642W WO2022212576A1 WO 2022212576 A1 WO2022212576 A1 WO 2022212576A1 US 2022022642 W US2022022642 W US 2022022642W WO 2022212576 A1 WO2022212576 A1 WO 2022212576A1
Authority
WO
WIPO (PCT)
Prior art keywords
lnp
composition
tert
lipid
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/022642
Other languages
English (en)
French (fr)
Inventor
John Ramunas
Glenn Jeremy MARKOV
William Gillis OLSEN
Kyle Daniel Brewer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rejuvenation Technologies Inc
Original Assignee
Rejuvenation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rejuvenation Technologies Inc filed Critical Rejuvenation Technologies Inc
Priority to AU2022246851A priority Critical patent/AU2022246851A1/en
Priority to CA3215112A priority patent/CA3215112A1/en
Priority to JP2023560598A priority patent/JP2024513048A/ja
Priority to IL307319A priority patent/IL307319A/en
Priority to EP22782138.6A priority patent/EP4312942A4/en
Priority to CN202280026001.6A priority patent/CN117396193A/zh
Publication of WO2022212576A1 publication Critical patent/WO2022212576A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • RNA ribonucleic acid
  • the present disclosure relates generally to compositions and methods for delivery of ribonucleic acid (RNA) therapies in the treatment of lung and fibrotic diseases.
  • RNA ribonucleic acid
  • Numerous lung diseases have been identified for which there is no current treatment. Lung diseases, e.g., pulmonary fibrosis, interstitial lung disease, and lung cancer, often induce fibrosis as part of disease progression, which further limits the extent to which patient recovery can occur. Delivery of polynucleotides to the lung for the treatment of lung disease are one method of treatment in development; however, the compositions and methods for delivery of these treatments are in need of improvement, and no treatment has been developed for treating the resulting fibrosis.
  • mRNAs polynucleotides
  • the lung cells include lung alveolar epithelium and vascular endothelium, and the delivery vehicles disclosed herein are useful for delivery of mRNA useful for the treatment or prevention of lung diseases and disorders.
  • the mRNA delivered to lung cells encodes a protein useful for treatment of a lung disease or disorder.
  • the mRNA encodes a TERT protein.
  • the protein is an antigen of a pathogen.
  • the lung diseases and disorder include, but are not limited to: pulmonary fibrosis, idiopathic pulmonary fibrosis, emphysema, interstitial lung diseases, chronic obstructive pulmonary disease (COPD), a lung infection, pneumonia, tuberculosis, gastric reflux, lung cancer, cystic fibrosis, dyskeratosis congenita, Alpha-1 antitrypsin deficiency, and other acquired or genetic diseases of the lung.
  • COPD chronic obstructive pulmonary disease
  • compositions comprising TERT mRNA may prevent, reverse or treat fibrosis and other pathological features of fibrotic disease and/or lung disease leading to improvements in overall organ function and subject health.
  • compositions comprising one or more synthetic messenger ribonucleic acids (mRNAs) encoding telomerase reverse transcriptase (TERT).
  • the composition comprises: (i) a ribonucleic acid (RNA) encoding telomerase reverse transcriptase (TERT) and (ii) a delivery vehicle, wherein the RNA encoding TERT comprises one or more modified nucleotides and wherein the delivery vehicle of (ii) is operably-linked to the RNA encoding TERT.
  • the delivery vehicle comprises one or more of a nanoparticle, a liposome, a cationic lipid, an exosome, an extracellular vesicle, a lipid nanoparticle, a natural lipoprotein particle, and an artificial lipoprotein particle.
  • the delivery vehicle comprises a lipid nanoparticle (LNP).
  • the delivery vehicle comprises a cationic lipid.
  • the delivery vehicle comprises a targeting moiety.
  • the targeting lipid results in the delivery vehicle specifically or selectively interacting with a lung cell.
  • the targeting moiety comprises cholesterol.
  • the targeting moiety is a lipid which specifically or selectively interacts with a lung cell.
  • the targeting lipid comprises 1,2-dioleoyl-3- trimethylammonium-propane (DOTAP), N,N-distearyl-N,N-dimethylarnmonium bromide (DABB), or 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (EPC).
  • DOTAP 1,2-dioleoyl-3- trimethylammonium-propane
  • DABB N,N-distearyl-N,N-dimethylarnmonium bromide
  • EPC 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine
  • the delivery vehicle comprises a compound of Formula I: wherein R 1a and R 1b each independently represents an alkylene group having 1 to 6 carbon atoms, wherein X a and X b are each independently an acyclic alkyl tertiary amino group having 1 to 6 carbon atoms and 1 tertiary amino group, or 2 to 5 carbon atoms, and A cyclic alkylene tertiary amino group having 1 to 2 tertiary amino groups, wherein R 2a and R 2b each independently represent an alkylene group having 8 or less carbon atoms or an oxydialkylene group, wherein Y a and Y b each independently represent an ester bond, an amide bond, a carbamate bond, an ether bond or a urea bond; wherein Z a and Z b are each independently a divalent group derived from an aromatic compound
  • compositions of the disclosure including those in which the delivery vehicle is a lipid nanoparticle (LNP), the compound of Formula I is: .
  • the compound of Formula I is: [0014] In some embodiments of the compositions of the disclosure, including those in which the delivery vehicle is a lipid nanoparticle (LNP), the compound of Formula I is: [0015] In some embodiments of the compositions of the disclosure, including those in which the delivery vehicle is a lipid nanoparticle (LNP), the compound of Formula I is: . [0016] In some embodiments of the compositions of the disclosure, including those in which the delivery vehicle is a lipid nanoparticle (LNP), the compound of Formula I is: .
  • the compound of Formula I is: [0017] In some embodiments of the compositions of the disclosure, including those in which the delivery vehicle is a lipid nanoparticle (LNP), the compound of Formula I is: . [0018] In some embodiments of the compositions of the disclosure, including those in which the delivery vehicle is a lipid nanoparticle (LNP), the compound of Formula I is: [0019] In some embodiments, the RNA comprise a sequence of SEQ ID NOS: 1-5, 30-31, or 37-40, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the RNA comprises a 5 ⁇ cap.
  • the 5 ⁇ cap comprises an anti-reverse cap analog (ARCA).
  • the ARCA comprises an 3′-O-Me-m7G(5′)ppp(5′)G structure.
  • the 5 ⁇ cap comprises m7G(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OMeA)pG.
  • the 5 ⁇ cap comprises m7(3 ⁇ OMeG)(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OMeA)pG.
  • the RNA further comprises at least one untranslated region (UTR).
  • the UTR may comprise a sequence of SEQ ID NOs: 32-36, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the at least one UTR is positioned 5′ to the RNA encoding TERT.
  • the at least one UTR is positioned 3′ to the RNA encoding TERT.
  • the UTR comprises a human sequence. In some embodiments, the UTR comprises a non-human or synthetic sequence. In some embodiments, the UTR comprises a chimeric sequence. In some embodiments, the UTR increases stability, increases half-life, increases a transcription rate or decreases a time until initiation of transcription of the RNA encoding TERT. In some embodiments, the UTR comprises a sequence having at least 70% identity to a UTR sequence isolated or derived from one or more of ⁇ -globin, ⁇ -globin, c-fos, and a tobacco etch virus.
  • the one or more modified nucleotides of the RNA encoding TERT comprise one or more of a modified adenine or analog thereof, a modified cytidine or analog thereof, a modified guanosine or analog thereof, and a modified uridine or analog thereof.
  • the one or more modified nucleotides of the RNA encoding TERT comprise one or more of 1-methylpseudouridine also known as N1- Methylpseudouridine, pseudouridine (N1m), 2-thiouridine, and 5-methylcytidine.
  • the one or more modified nucleotides of the RNA encoding TERT comprise 5- methoxyuridine (5-moU). In some embodiments, the one or more modified nucleotides of the RNA encoding TERT comprise one or more of m1A 1-methyladenosine, m6A N6- methyladenosine, Am 2′-O-methyladenosine, i6A N6-isopentenyladenosine, io6A N6-(cis- hydroxyisopentenyl)adenosine, ms2io6A 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, g6A N6-glycinylcarbamoyladenosine, t6A N6-threonylcarbamoyladenosine, ms2t6A 2-methylthio-N6-threonyl carbamoyladenosine
  • the delivery vehicle comprises the RNA encoding TERT.
  • one or more of a surface, a layer or a volume of the delivery vehicle comprises the RNA encoding TERT.
  • the surface comprises an outer surface or an inner surface.
  • the layer comprises a lipid monolayer or lipid bi-layer.
  • the volume comprises an internal volume.
  • the disclosure provides a composition comprising a (i) a ribonucleic acid (RNA) encoding telomerase reverse transcriptase (TERT) and (ii) a delivery vehicle, wherein the RNA encoding TERT comprises one or more modified nucleotides and wherein the delivery vehicle of (ii) is operably-linked to the RNA encoding TERT.
  • the compositions of the disclosure including those in which the delivery vehicle is a lipid nanoparticle (LNP), the composition further comprises a ribonucleic acid (RNA) encoding TElomerase RNA Component (TERC).
  • the delivery vehicle is operably-linked to a ribonucleic acid (RNA) encoding TElomerase RNA Component (TERC).
  • RNA ribonucleic acid
  • TERC TElomerase RNA Component
  • the delivery vehicle comprises the RNA encoding TERC.
  • one or more of a surface, a layer or a volume of the delivery vehicle comprises the RNA encoding TERC.
  • the surface comprises an outer surface or an inner surface.
  • the layer comprises a lipid monolayer or lipid bi-layer.
  • the volume comprises an internal volume.
  • the RNA encoding TERT comprises a sequence of SEQ ID NOS: 1-5, 7, 9, 14-17, 19, 21, 23, 25, 27, 29-31, 37-40, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the RNA encoding TERT comprises a UTR sequence of SEQ ID NOS: 32-34, 35, and 36, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the RNA comprises a self-replicating RNA.
  • the RNA comprises a circular RNA.
  • the disclosure provides a method of increasing telomerase activity in a cell, the method comprising contacting the cell and the composition of the disclosure.
  • the cell is in vivo, ex vivo or in vitro.
  • the disclosure provides a method of extending telomeres in a cell, the method comprising contacting the cell and the composition of the disclosure.
  • the cell is in vivo, ex vivo or in vitro.
  • the disclosure provides a cell comprising the composition of the disclosure.
  • the disclosure provides a formulation comprising the cell of the disclosure, which comprises a composition of the disclosure.
  • a plurality of cells comprises a cell of the disclosure, which comprises a composition of the disclosure.
  • each cell of the plurality is a cell of the disclosure, which comprises a composition of the disclosure.
  • the disclosure provides a method of treating a disease or disorder comprising administering to a subject an effective amount of a composition of the disclosure.
  • the disclosure provides a method of treating a disease or disorder comprising administering to a subject an effective amount of a cell of the disclosure, which comprises a composition of the disclosure.
  • the disclosure provides a method of treating a disease or disorder comprising administering to a subject an effective amount of a formulation of the disclosure.
  • the disclosure provides a method of delaying the onset of a disease comprising administering to a subject an effective amount of a composition of the disclosure.
  • the disclosure provides a method of delaying the onset of a disease comprising administering to a subject an effective amount of a cell of the disclosure, which comprises a composition of the disclosure.
  • the disclosure provides a method of delaying the onset of a disease comprising administering to a subject an effective amount of a formulation of the disclosure.
  • FIG.1 is a schematic illustrating long-term therapeutic benefit from transient, rapid telomere extension via telomerase reverse transcriptase (TERT) mRNA.
  • TERT telomerase reverse transcriptase
  • telomere activity resulting from TERT mRNA delivery rapidly extends telomeres in a brief period, before the mRNA is turned over, thus allowing the protective anti-cancer mechanism of telomere-shortening to function most of the time.
  • normal telomerase activity and telomere shortening is present, and therefore the anti-cancer safety mechanism of telomere shortening to prevent out-of- control proliferation remains intact, while the risk of short telomere-related disease remains low.
  • FIG.2 depicts a representative dynamic light scattering (DLS) plot of the mRNA- LNPs made using exemplary lipid components disclosed here.
  • FIG.3 depicts bioluminescent imaging of whole organs in mice that were injected with mRNA-LNPs.
  • FIGS. 5A-5B depict measurements of telomerase activity in mouse lung after delivery of TERT mRNA-LNP (FIG. 5B) and in mouse lung of an untreated control (FIG. 5A).
  • FIG.6A is a bar graph depicting the transfection efficiency of an exemplary lung delivery vehicle formulation.
  • FIGS.6B-6F depict representative images of lung sections harvested from the mice as described above, with the reporter protein shown as a darkened stain.
  • FIGS.7A-7C depict computed tomography (CT) X-ray scans of mouse lungs tested for lung fibrosis.
  • FIG.7D is a bar graph quantifying the results shown in FIGS.7A-7C.
  • FIG. 8 depicts a graph showing the mortality of mice dosed with the formulation of Table 6A compared to other formulations of lung-targeted LNPs.
  • FIGS. 9A-9D depict various lung samples from mice treated with bleomycin for inducing lung fibrosis, and treated with CRE mRNA or saline to show delivery of the mRNA to alveolar cells.
  • FIG. 10 shows the lung luminescence from intravenous (IV) and tracheal (OA) delivery of luciferase mRNA to the lung with SS-OP DOTAP and cKK DOTAP LNP formulations.
  • FIG.11 shows preferential delivery to the lung of the SS-OP DOTAP formulation administered intravenously. From left to right the LNP formulations of the dish are (1) SS-OP DOTAP 75:1 delivered orally; (2) SS-OP DOTAP 75:1 delivered intravenously; (3) PBS control (no LNP); and (4) cKK DOTAP 40:1 delivered orally.
  • FIG. 11 shows preferential delivery to the lung of the SS-OP DOTAP formulation administered intravenously. From left to right the LNP formulations of the dish are (1) SS-OP DOTAP 75:1 delivered orally; (2) SS-OP DOTAP 75:1 delivered intravenously; (3) PBS control (no LNP); and (4) cKK DOTAP 40:1 delivered orally.
  • FIG. 12 shows the percentage of Tomato (+) cells in lung parenchyma with intravenous delivery of LNP formulations containing CRE mRNA.
  • FIG.13 shows lung luminescence relative to the flow rates used to formulate the LNP-compositions delivering firefly luciferase mRNA.
  • FIG. 14 shows the ex vivo bioluminescence of the LNP formulations delivering luciferase RNA, wherein no structural lipid or cholesterol was required for RNA delivery.
  • FIG. 15 shows the ex vivo lung mean radiance of LNP formulations delivering luciferase mRNA, wherein the RNA to LNP ratio was varied according to the ratios shown.
  • FIG. 14 shows the ex vivo bioluminescence of the LNP formulations delivering luciferase mRNA, wherein the RNA to LNP ratio was varied according to the ratios shown.
  • FIGS.17A and 17B show the ex vivo lung mean radiance of the LNP formulations delivering luciferase mRNA, wherein the percentage of PEGylated lipid is varied in the formulation.
  • FIGS.18A and 18B show the ex vivo lung mean radiance of the LNP formulations delivering luciferase mRNA, wherein the percentage of PEGylated lipid is below 1.5%, or not present in the formulation.
  • FIG.19 shows the ex vivo lung mean radiance of the LNP formulations delivering luciferase mRNA, wherein the percentage of DOTAP is varied in the formulation.
  • FIGS.20A and 20B show the ex vivo preferential delivery to lung of example LNP formulations, wherein the percentage of DOTAP is varied.
  • FIG. 20A shows the liver mean radiance of the LNP formulations delivering luciferase mRNA according to the percentage of DOTAP.
  • FIG.20B shows the lung/liver delivery ratio of the LNP formulations according to the percentage of DOTAP.
  • FIGS. 21A and 21B show transfection of the LNP formulations in alveolar epithelial cells.
  • FIG. 22 shows SS-OP DOTAP delivery of a therapeutic mRNA as a disease treatment, using the SS-OP DOTAP LNPs of Table 6A, comprising TERT mRNA.
  • the LNP TERT mRNA formulations were delivered to a lung fibrosis model mouse, induced by bleomycin at Day 0. Relative to the control mRNA, delivery of the TERT mRNA extended the survival rate of the mouse by 210% at the endpoint.
  • compositions and methods of the disclosure provide lipid nanoparticles (LNP) comprising an SS-OP lipid, or analog thereof, such as the compounds of Formula I described herein, and a cationic lipid for intravenous delivery to the lung, e.g., for the treatment of lung disease and/or lung fibrosis.
  • LNP lipid nanoparticles
  • the SS-OP lipid or analog thereof may be replaced or combined with a cKK lipid or analog thereof.
  • the aforementioned LNPs may have improved lung transduction efficiency and/or lung specificity compared to known LNP formulations.
  • RNA ribonucleic acids
  • TERT telomerase reverse transcriptase
  • the RNA encoded TERT may optionally be delivered with the aforementioned SS-OP LNP compositions, or with other LNPs known in the art.
  • Telomerase reverse transcriptase is an enzyme known to maintain and extend chromosomal ends (telomeres).
  • the TERT enzyme is a catalytic subunit of the ribonucleoprotein telomerase. TERT adds simple sequence repeats to telomeres by copying a template sequence 5 ⁇ -GGTTAG-3 ⁇ within the RNA component of telomerase.
  • TERT translocates between the nucleus and cytoplasm and has been shown to be a critical factor in a number of other biological processes, including cell proliferation and cancer metastasis. Thus, the level of TERT in the nucleus may be a critical step in regulating cell and organismal health.
  • Telomerase reverse transcriptase is also known in the art as TRT, cutaneous malignant melanoma 9 (CMM9), dyskeratosis congenita autosomal dominant 2 (DKCA2), autosomal recessive dyskeratosis congenita-4 (DKCB4), human ever shorter telomeres 2 (HEST2), pulmonary fibrosis/bone marrow failure telomere related 1 (PFBMFT1), telomerase catalytic subunit (TCS1), and telomerase associated protein 2 (TP2).
  • CMM9 cutaneous malignant melanoma 9
  • DKCA2 dyskeratosis congenita autosomal dominant 2
  • DKCB4 autosomal recessive dyskeratosis congenita-4
  • HEST2 human ever shorter telomeres 2
  • PFBMFT1 pulmonary fibrosis/bone marrow failure telomere related 1
  • TCS1 telomerase catalytic subunit
  • the treatments described herein may stop, slow, or reverse progression of a fibrotic disease, e.g., a lung disease, or other lung diseases.
  • a fibrotic disease e.g., a lung disease, or other lung diseases.
  • TERT mRNA is transient and only requires a few hours to extend telomeres in human cells before being degraded. Therefore, TERT mRNA leaves the protective anti- cancer telomere shortening mechanism intact.
  • the present disclosure provides compositions and methods for delivery of TERT mRNA and treatment of fibrotic diseases and lung diseases.
  • telomeres shorten by approximately 30–100 base pairs per year due to oxidation and incomplete DNA replication during S phase of the cell cycle (Kurenova EV, et al. Telomere functions.
  • telomere shortening in many progenitor cell types.
  • TERC polynucleotide template
  • spermatogenic lineage in which telomerase is active enough to maintain telomere length over the human lifespan (Takubo K, Aida J, Izumiyama- Shimomura N, et al. Changes of telomere length with aging. Geriatric Gerontology Int 2010; 10 Suppl 1:S197-206).
  • telomeres comprise repetitive DNA sequences at the ends of linear chromosomes that, when sufficiently long, can allow each chromosome end to form a loop that protects the ends from acting as double-stranded or single-stranded DNA breaks.
  • Telomeres can shorten over time, due in part to oxidative damage and incomplete DNA replication, eventually leading to critically short telomeres unable to form the protective loop, exposure of the chromosome ends, chromosome-chromosome fusions, DNA damage responses, and cellular senescence, apoptosis, or malignancy.
  • Telomere length maintenance can play a role in preventing cellular senescence and apoptosis and resulting cellular and organ dysfunction. In many diseases, the need for cell replication to replace cells damaged or killed by the underlying disease mechanism shortens telomeres more rapidly than normal, exhausting the replicative capacity of cells, and leading to tissue dysfunction, exacerbated or additional symptoms, disability, or death.
  • telomere enzyme can be linked to fatal inherited diseases of inadequate telomere maintenance, including dyskeratosis congenita and forms of lung fibrosis, lung disease and aplastic anemia. Chromosome-chromosome fusions and cellular senescence due to short telomeres can increase risk of cancer. Short telomeres are also associated with deleterious conditions and diseases of aging and poor outcomes in a large number of diseases.
  • Lung diseases contributing to lung fibrosis include but are not limited to: pulmonary fibrosis, lung cancer, familial pulmonary fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis associated with dyskeratosis congenita, an interstitial lung disease, pneumonia, interstitial pneumonia, tuberculosis, bronchitis, emphysema, lung cancer, chronic obstructive pulmonary disease (COPD), aging-associated fibrosis, pulmonary hypertension, asthma, and cystic fibrosis.
  • COPD chronic obstructive pulmonary disease
  • telomere extension motivates a need for safe and effective treatments to extend telomeres in animal cells in vivo and/or in vitro, and safe and effective compositions and methods for delivering therapies to the animal cells to extend telomeres. Further, there is a need to safely and rapidly extend telomeres in cells for use in cell therapy, cell and tissue engineering, and regenerative medicine. At the same time, however, there can be a danger in the constitutive, as opposed to transient, activation of telomerase activity. Indeed, for cell therapy applications, there is a need to avoid cell immortalization.
  • telomere activity can be advantageous for safety, e.g., if the elevated telomerase activity is not only brief but extends telomeres rapidly enough that the treatment does not need to be repeated continuously.
  • therapies that safely extend telomeres to potentially prevent, delay, ameliorate, or treat these and other conditions and diseases, to do the same for the gradual decline in physical form and function and mental function that accompanies chronological aging, and to enable cell therapies and regenerative medicine.
  • improved methods of delivering these therapies e.g., nucleic acid molecules encoding telomerase, to cells.
  • reference to “a drug candidate” refers to one or mixtures of such candidates
  • reference to “the method” includes reference to equivalent steps and methods known to those skilled in the art, and so forth.
  • the term “approximately” or “about,” as applied to one or more values of interest refers to a value that is similar in magnitude and/or within a similar range to a stated reference value.
  • the term “approximately” or “about” may refer to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
  • G,” “C,” “A,” “T” and “U” generally stand for the bases, guanine, cytosine, adenine, thymidine and uracil, respectively.
  • Nucleobases can form nucleosides by the addition of a five carbon sugar. If the sugar is ribose then the nucleoside is a ribonucleoside.
  • Nucleosides can in turn form nucleotides by the addition of one or more linker groups such as phosphate groups. Nucleotides can in turn form polymers (polynucleotides) which include short polymers (oligonucleotides).
  • base can also refer to a modified base, nucleobase, nucleoside, ribonucleoside, nucleotide, or ribonucleotide, as further detailed below, or a surrogate replacement moiety (see, e.g., Table 2 and elsewhere herein).
  • guanine, cytosine, adenine, thymidine, uracil can be replaced by other moieties without substantially impairing one or more of certain properties (such as base pairing properties, translatability, or protein binding properties) of an oligonucleotide or polynucleotide comprising a nucleotide bearing such replacement moiety. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the disclosure.
  • ribose can be replaced with other moieties without impairing certain properties (such as base pairing properties, translatability, or protein binding properties) of an oligonucleotide or polynucleotide comprising a nucleotide bearing such replacement moiety. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the disclosure. Similarly, the skilled person is well aware that phosphate can be replaced with other moieties without impairing certain properties (such as base pairing properties, translatability, or protein binding properties) of an oligonucleotide or polynucleotide comprising a nucleotide bearing such replacement moiety.
  • polypeptide As used herein, the terms “polypeptide,” “peptide,” and “protein” refer to polymers of amino acids of any length. The terms also encompass an amino acid polymer that has been modified; for example, to include disulfide bond formation, glycosylation, lipidation, phosphorylation, or conjugation with a labeling component.
  • identity As used herein, the terms “identity” and “identical” refer, with respect to a polypeptide or polynucleotide sequence-of-interest, to the percentage of exact matching residues in an alignment of that the sequence-of-interest to a reference sequence, such as an alignment generated by the BLAST algorithm.
  • a sequence-of-interest “shares at least x% identity to” a reference sequence if, when the reference sequence is aligned (as a query sequence) is aligned to the sequence-of-interest (as subject sequence), at least x% (rounded down) of the residues in the subject sequence are aligned as an exact match to a corresponding residue in the query sequence, the denominator being the full length of the reference sequence plus the lengths of any gaps inserted into the reference sequence by alignment of the reference sequence to the sequence-of-interest.
  • the subject sequence has variable positions (e.g., residues denoted X), an alignment to any residue in the query sequence is counted as a match.
  • sequence alignments may be performed using the NCBI Blast service (BLAST+ version 2.12.0) or another program giving the same results.
  • wild-type refers to a nucleotide sequence, e.g. gene, or gene product, e.g. RNA or polypeptide, that is present in a wild-type cell, tissue, organ or organism.
  • variant refers to a mutant of a reference polynucleotide or polypeptide sequence, for example a native polynucleotide or polypeptide sequence, i.e., having less than 100% sequence identity with the reference polynucleotide or polypeptide sequence.
  • a variant comprises at least one nucleotide difference (e.g., nucleotide substitution, nucleotide insertion, nucleotide deletion) or one amino acid difference (e.g., amino acid substitution, amino acid insertion, amino acid deletion) relative to a reference polynucleotide sequence, e.g. a native polynucleotide or polypeptide sequence.
  • a variant may be a polynucleotide having a sequence identity of 50% or more, 60% or more, or 70% or more with a full length native polynucleotide sequence, e.g.
  • a variant may be a polypeptide having a sequence identity of 70% or more with a full length native polypeptide sequence, e.g. an identity of 75% or 80% or more, such as 85%, 90%, or 95% or more, for example, 98% or 99% identity with the full length native polypeptide sequence.
  • Variants may also include variant fragments of a reference, e.g. native, sequence sharing a sequence identity of 70% or more with a fragment of the reference, e.g. native, sequence, e.g.
  • the term “codon optimized” refers to any process used to improve gene expression and increase the translational efficiency of a gene of interest by accommodating the codon bias of the host organism, and/or to reduce the immunogenicity of the polynucleotide.
  • the terms “treating” or “treatment” are used herein to generally mean obtaining a desired pharmacologic and/or physiologic effect with a therapeutic agent. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof, e.g.
  • Treatment covers any treatment of a disease in a mammal, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting or slowing the onset or development of the disease; or (c) relieving the disease, e.g., causing regression of the disease or symptoms associated with the disease.
  • the therapeutic agent may be administered before, during or after the onset of disease.
  • the treatment of ongoing disease where the treatment stabilizes or reduces the undesirable clinical symptoms of the patient, may be of particular interest.
  • treatment is performed prior to complete loss of function in the affected tissues.
  • the subject therapy will be administered before the symptomatic stage of the disease; and, in some embodiments, during the symptomatic stage of the disease; and, in some embodiments, after the symptomatic stage of the disease.
  • therapies as described herein treat fibrotic diseases or lung diseases, including but not limited to fibrotic lung diseases.
  • the terms “individual,” “subject,” and “patient” are used interchangeably herein and refer to any subject for whom treatment or therapy is desired.
  • the subject may be a mammalian subject.
  • Mammalian subjects include, e. g., humans, non-human primates, rodents, (e.g., rats, mice), lagomorphs (e.g., rabbits), ungulates (e.g., cows, sheep, pigs, horses, goats, and the like), etc.
  • the subject is a human.
  • the subject is a non-human primate, for example a cynomolgus monkey.
  • the subject is a companion or service animal (e.g. cats or dogs).
  • a subject “in need thereof,” as used herein, refers to any subject suffering from or identified to be at risk of developing a fibrotic disease or lung disease.
  • RNA ribonucleic acid
  • a synthetic ribonucleic acid (RNA) as used herein may refer to any RNA sequence comprising a mutation (point or deletion) or additional nucleotides not found in the wild type sequence.
  • a synthetic TERT messenger RNA may refer to a wild type sequence encoding a human TERT sequence, flanked by the addition of 1, 2, 3, 10, 100 or more nucleotides.
  • the nucleotides themselves may encode amino acids distinct from the wild type, or be modified to reduce immunogenicity in the cell or tissue.
  • An mRNA sequence in some embodiments may comprise any of the following modifications, including but not limited to an untranslated region (UTR), a 5 ⁇ cap, and a poly-adenosine tail.
  • the RNA may be circular and/or self-replicating. [0090] Illustrative methods of making circular mRNAs are provided in Chen et al. Science.
  • a composition may comprise a reverse transcriptase telomerase (TERT) mRNA sequence to treat one or more phenotypes or symptoms associated with a fibrotic disease or lung disease.
  • a TERT mRNA refers to an mRNA encoding any full length, functional fragment or portion of a TERT protein, including wild type sequences or variants thereof.
  • a TERT mRNA may comprise a codon-optimized sequence.
  • a TERT mRNA may comprise a uridine depleted human TERT sequence.
  • the codon-optimized sequence may comprise SEQ ID NO: 1, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • a TERT mRNA may comprise a mutant human TERT sequence.
  • the mutant human TERT mRNA may encode a Y707F mutation in the resulting peptide sequence.
  • a mutation in the TERT mRNA sequence encodes a mutation in the nuclear export signal which may result in nuclear retention of the TERT peptide.
  • the mutant TERT mRNA sequence may comprise SEQ ID NO: 2, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • a mouse TERT mRNA may comprise a codon-optimized sequence.
  • a TERT mRNA may comprise a uridine depleted mouse TERT sequence.
  • the codon-optimized sequence may comprise SEQ ID NO: 3, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • a mouse TERT mRNA may comprise a mutant mouse TERT sequence.
  • the mutant mouse TERT mRNA may encode a Y707F mutation in the resulting peptide sequence.
  • a mutation in the TERT mRNA sequence encodes a mutation in the nuclear export signal which may result in nuclear retention of the TERT peptide.
  • the mutant mouse TERT mRNA sequence may comprise SEQ ID NO: 4, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • a mouse TERT mRNA may comprise a mutant mouse TERT sequence.
  • the mutant mouse TERT mRNA may encode a Y697F mutation in the resulting peptide sequence.
  • a mutation in the TERT mRNA sequence encodes a mutation in the nuclear export signal which may result in nuclear retention of the TERT peptide.
  • the mutant mouse TERT mRNA sequence may comprise a sequence of SEQ ID NO: 5, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the compositions of the disclosure may comprise a ribonucleic acid, e.g., a synthetic ribonucleic acid coding for a telomerase reverse transcriptase (TERT), wherein telomeres are extended within a cell treated with the compound.
  • TERT telomerase reverse transcriptase
  • the ribonucleic acids used in the transient expression of TERT can comprise a ribonucleic acid coding for a TERT protein.
  • the ribonucleic acids can further comprise one or more sequences that affect the expression and/or stability of the ribonucleic acid in a cell.
  • the ribonucleic acids can contain a 5′ cap and untranslated region (UTR) to the 5′ and/or 3′ side of the coding sequence.
  • the ribonucleic acids may further contain a 3′ tail, such as a poly-A tail.
  • the poly-A tail can, for example, increase the stability of the ribonucleic acid.
  • the poly-A tail comprises at least 25 nucleotides, at least 50 nucleotides, at least 75 nucleotides, at least 100 nucleotides, at least 125 nucleotides, at least 150 nucleotides, at least 200 nucleotides, at least 225 nucleotides, at least250 nucleotides.
  • the poly-A tail comprises between 1 and 25 nucleotides, between 25 and 50 nucleotides, between 50 and 75 nucleotides, between 75 and 100 nucleotides, between 100 and 125 nucleotides, between 125 and 150 nucleotides, between 150 and 175 nucleotides, between 175 and 200 nucleotides, between 200 and 225 nucleotides, or between 225 and 250 nucleotides, inclusive of the endpoints for each range. In some embodiments, the poly-A tail comprises between 100 and 200 nucleotides, inclusive of the endpoints. [0098] In some embodiments, the 5′ cap of the ribonucleic acid is a non-immunogenic cap.
  • the 5′ cap may increase the translation of the ribonucleic acid.
  • the 5′ cap may be treated with phosphatase to modulate the innate immunogenicity of the ribonucleic acid.
  • the 5′ cap is an anti-reverse cap analog (“ARCA”), such as a 3′-O-Me-m7G(5′)ppp(5′)G RNA cap structure analog.
  • the 5 ⁇ cap is m7G(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OmeA)pG (also known as CleanCap ⁇ AG).
  • the 5 ⁇ cap is m7(3 ⁇ OmeG)(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OmeA)pG (also known as CleanCap®AG (3 ⁇ OMe)).
  • the above features, or others may increase translation of the TERT protein encoded by the ribonucleic acid, may increase or decrease the stability of the ribonucleic acid itself in a cell type-specific or cell type-independent manner, or may do both.
  • the 5′ UTR and/or the 3′ UTR are from a gene that has a very stable mRNA and/or an mRNA that is rapidly translated, for example, ⁇ -globin or ⁇ -globin, c-fos, or tobacco etch virus.
  • the 5′ UTR and 3′ UTR are from different genes or are from different species than the species into which the compositions are being delivered.
  • the UTRs may also be assemblies of parts of UTRs from the mRNAs of different genes, where the parts are selected to achieve a certain combination of stability and efficiency of translation.
  • the UTRs may also comprise designed sequences that confer properties to the RNA such as cell type-specific stability or cell type-independent stability.
  • the ribonucleic acids of the present disclosure may comprise one or more modified nucleosides, and/or comprise primary sequences of nucleosides, that modulate translation, stability, or immunogenicity of the RNA.
  • Most mature RNA molecules in eukaryotic cells contain nucleosides that are modified versions of the canonical unmodified RNA nucleosides, adenine, cytidine, guanosine, and uridine.
  • the 5 ⁇ cap of mature RNA comprises a modified nucleoside, and other modified nucleosides often occur elsewhere in the RNA. Those modifications may prevent the RNA from being recognized as a foreign RNA.
  • Synthetic RNA molecules made using certain nucleosides are much less immunogenic than unmodified RNA.
  • the immunogenicity can be reduced even further by purifying the synthetic mRNA, for example by using high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • the modified nucleosides may be, for example, chosen from the nucleosides listed below.
  • the nucleosides are, in some embodiments, pseudouridine, 1-methylpseudouridine, 2-thiouridine, 5-methoxyuridine, or 5- methylcytidine.
  • the primary sequence may be modified in ways that increase or decrease immunogenicity. Under some circumstances, it may be desirable for the modified RNA to retain some immunogenicity.
  • the ribonucleic acids of the instant compositions comprise a 1-methylpseudouridine, pseudouridine, a 5-methoxyuridine (5-moU), a 2-thiouridine, a 5-methylcytidine, or another modified nucleoside.
  • Modified nucleosides found in eukaryotic cells include m1A 1-methyladenosine, m6A N6-methyladenosine, Am 2′- O-methyladenosine, i6A N6-isopentenyladenosine, io6A N6-(cis- hydroxyisopentenyl)adenosine, ms2io6A 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, g6A N6-glycinylcarbamoyladenosine, t6A N6-threonylcarbamoyladenosine, ms2t6A 2-methylthio-N6-threonyl carbamoyladenosine, Ar(p) 2′-O-ribosyladenosine (phosphate), m62A N6,N6-dimethyladenosine, m6Am N6,2′-O
  • the presence of the modified nucleosides, and/or sequences of nucleosides that alter secondary structure of the RNA and/or binding of RNA to RNA binding proteins or microRNA, may enable mRNA to avoid activation of an immune response mediated by various receptors, including the Toll-like receptors and RIG-1.
  • Non-immunogenic mRNA has been used as a therapeutic agent in mice via topical delivery. Kormann et al. (2011) Nature Biotechnology 29:154-157.
  • the ribonucleic acids comprise more than one of the above nucleosides or combination of the above nucleosides.
  • the ribonucleic acids comprise 1-methylpseudouridine, 5- methoxyuridine, or pseudouridine and 5-methylcytidine.
  • an immune response to the mRNA may be desired, and the RNA may be modified to induce an optimal level of innate immunity. In other embodiments, an immune response to the mRNA may not be desired, and the RNA may be modified in order to minimize such a reaction. The RNA can be modified for either situation.
  • the ribonucleic acid molecules can be synthetic ribonucleic acids.
  • the term “synthetic”, as used herein, can mean that the ribonucleic acids are in some embodiments prepared using the tools of molecular biology under the direction of a human, for example as described below.
  • the synthetic ribonucleic acids may, for example, be prepared by in vitro synthesis using cellular extracts or purified enzymes and nucleic acid templates.
  • the synthetic ribonucleic acids may in some embodiments be prepared by chemical synthesis, either partially or completely.
  • the synthetic ribonucleic acids may in some embodiments be prepared by engineered expression in a cell, followed by disruption of the cell and at least partial purification of the ribonucleic acid.
  • the ribonucleic acids of the present disclosure may be prepared using a variety of techniques, as would be understood by one of ordinary skill in the art.
  • the ribonucleic acids may be prepared by in vitro synthesis.
  • the ribonucleic acids may be prepared by chemical synthesis.
  • the ribonucleic acids may be prepared by a combination of in vitro synthesis and chemical synthesis.
  • synthetic should be understood to include ribonucleic acids that are prepared either by chemical synthesis, by in vitro synthesis, by expression in vivo and at least partial purification, or by a combination of such, or other, chemical or molecular biological methods.
  • the ribonucleic acids may, in some embodiments, be purified. As noted above, purification may reduce immunogenicity of the ribonucleic acids and may be advantageous in some circumstances. In some embodiments, the ribonucleic acids are purified by one or more of HPLC, DNAse treatment, protease treatment, or by affinity capture and elution.
  • the protein structure of TERT can include at least three distinct domains: a long extension at the amino-terminus (the N-terminal extension, NTE) that contains conserved domains and an unstructured linker region; a catalytic reverse-transcriptase domain in the middle of the primary sequence that includes seven conserved reverse transcriptase (RT) motifs; and a short extension at the carboxyl-terminus.
  • NTE N-terminal extension
  • RT conserved reverse transcriptase
  • the ribonucleic acid codes for a full-length TERT.
  • the ribonucleic acid codes for a catalytic reverse transcriptase domain of TERT.
  • the ribonucleic acid codes for a polypeptide having TERT activity.
  • TERT activity may be measured using known methods including the telomerase repeat amplification protocol (TRAP).
  • the TERT encoded by the ribonucleic acids of the instant disclosure may be a mammalian, avian, reptilian, or fish TERT.
  • the TERT is a mammalian TERT, such as human TERT. Meyerson et al. (1997) Cell 90:785-795; Nakamura et al. (1997) Science 277:955-959; Wick et al. (1999) Gene 232:97-106.
  • the amino acid sequence of two human TERT isoforms are available as NCBI Reference Sequences: NP_937983.2 and NP_001180305.1.
  • the amino acid sequence of human TERT isoform 1 may comprise or consist of the sequence of SEQ ID NO: 6 (also described at GenBank Accession No. NP_937983.2).
  • the nucleic acid sequence of human TERT isoform 1 may comprise or consist of the sequence of SEQ ID NO: 7 (also described at GenBank Accession No. NM_198253.3).
  • the amino acid sequence of human TERT isoform 2 may comprise or consist of the sequence of SEQ ID NO: 8 (also described at GenBank Accession No. NP_001180305.1).
  • the amino acid sequence of human TERT isoform 2 may comprise or consist of the sequence of SEQ ID NO: 9 (also described at GenBank Accession No.
  • a human TERT mRNA may comprise a wild type TERT sequence.
  • the wild type TERT sequence may comprise a sequence of SEQ ID NO: 30, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • a mouse TERT mRNA may comprise a wild type TERT sequence.
  • the wild type TERT sequence may comprise SEQ ID NO: 31, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • a TERT mRNA may comprise a nucleic acid sequence at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOS: 1- 5, 7, 9 or 30.
  • a TERT mRNA may encode a modified TERT protein containing one or more amino acid substitutions, deletions, and/or insertions as compared to SEQ ID NOS: 6 or 8, while retaining substantial TERT activity.
  • a TERT mRNA may encode an amino acid sequence at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% to SEQ ID NO: 6 or SEQ ID NO: 8.
  • a TERT mRNA may encode an amino acid sequence with a mutation of L55Q, P65A, V70M, A202T, A279T, V299M, H412Y, a deletion of residue 441, R522K, K570N, R631Q, G682D, V694M, Y697F, P704S, Y707F, A716T, P721R, T726M, Y772C, P785L, V791I, R811C, L841F, R865H, V867M, R901W, K902N, P923L, S948R, R979W, V1025F, A1062T, V1090M, T1110M, and/or F1127L relative to the amino acid sequences of SEQ ID NO: 6.
  • the TERT mRNA may encode a TERT isoform in which the translated protein lacks amino acid residues 711-722, 764-807, 808-1132, or 885-947 relative to the amino acid sequences of SEQ ID NO: 6. In some embodiments about 1, about 5, about 10, about 20, or about 100 amino acids preceding or following the domain are also deleted from the amino acid sequence of SEQ ID NO: 6.
  • the TERT mRNA may encode an amino acid sequence in which one or more of the protein regions are deleted or repeated relative to the amino acid sequences of SEQ ID NO: 6: residues 1-230 corresponding to the RNA-interacting domain 1, residues 58-197 corresponding to a “GQ” residue motif, residues 137-141 associated with the specificity of telomeric DNA and primer elongation, residues 210-320 corresponding to a disordered region, residues 231-324 associated with a linker sequence, residues 301-538 associated with oligomerization, residues 325-550 or 460-594 corresponding to an RNA- interacting domain, residues 376-521 corresponding to a “QFP” residue motif, residues 397- 417 corresponding to a “CP” residue motif, residues 825-884 corresponding to a DNA repeat template, residues 618-729 corresponding to a reverse transcriptase like element, residues 914- 928 associated with oligomerization
  • a TERT mRNA may comprise or consist of a nucleotide sequence at least at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identical to any subsequence of a disclosed nucleic acid sequence, e.g., any 100 base pair (bp), 200 bp, 300 bp, 400 bp, 500 bp, or more of a disclosed nucleic acid sequence.
  • a TERT mRNA may encode an amino acid sequence at least at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identical to any of one of the disclosed polypeptide sequences, or to any subsequence of a disclosed polypeptide sequence, e.g., any 50 amino acid (aa), 100 aa, 200 aa, 300 aa, 400 aa, 500 aa, or more of a disclosed polypeptide sequence.
  • Non-limiting TERT sequences of the disclosure include TERT nucleic acid and amino acid sequences listed in Table 1. Table 1: Non-human TERT sequences
  • an amino acid sequence of TERT may comprise or consist of a sequence of SEQ ID NOS: 6-8 or 10-13, or an amino acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • an amino acid sequence of a portion of TERT, functional or non-functional may comprise or consist of a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 99% identity to a subsequence of one or more of SEQ ID NOS: 6-8 or 10-13.
  • a nucleic acid sequence of TERT may comprise or consist of a sequence of SEQ ID Nos: 1-5, 7, 9, 14- 17, 30 or 31, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the amino acid sequence of non-human primate TERT isoform 1 may comprise or consist of the sequence of SEQ ID NO: 18 (also described at GenBank Accession No. XP_016808391.2).
  • the nucleic acid sequence of non-human primate TERT isoform 1 may comprise or consist of the sequence of SEQ ID NO: 19 (also described at GenBank Accession No. XM_016952902.2).
  • the amino acid sequence of non-human primate TERT isoform 2 may comprise or consist of the sequence of SEQ ID NO: 20, GenBank Accession No. PNI27662.1.
  • the nucleic acid sequence of non-human primate TERT isoform 2 may comprise or consist of the sequence of SEQ ID NO: 21 (reverse machine translation of GenBank Accession No. PNI27662.1).
  • the amino acid sequence of non-human primate TERT isoform 3 may comprise or consist of the sequence of SEQ ID NO: 22 (also described at GenBank Accession No. PNI27663.1).
  • the nucleic acid sequence of non-human primate TERT isoform 3 may comprise or consist of the sequence of SEQ ID NO: 23 (reverse machine translation of GenBank Accession No. PNI27663.1).
  • the amino acid sequence of non-human primate TERT isoform 4 may comprise or consist of the sequence of SEQ ID NO: 24 (also described at GenBank Accession No. PNI27664.1).
  • the nucleic acid sequence of non-human primate TERT isoform 4 may comprise or consist of the sequence of SEQ ID NO: 25 (reverse machine translation of GenBank Accession No. PNI27664.1).
  • the amino acid sequence of non-human primate TERT isoform 5 may comprise or consist of the sequence of SEQ ID NO: 26 (also described at GenBank Accession No. PNI27665.1).
  • the nucleic acid sequence of non-human primate TERT isoform 5 may comprise or consist of the sequence of SEQ ID NO: 27 (reverse machine translation of GenBank Accession No. PNI27665.1).
  • the amino acid sequence of non-human primate TERT isoform 6 may comprise or consist of the sequence of SEQ ID NO: 28 (also described at GenBank Accession No. PNI27666.1).
  • the nucleic acid sequence of non-human primate TERT isoform 6 may comprise or consist of the sequence of SEQ ID NO: 29 (reverse machine translation of GenBank Accession No. PNI27666.1).
  • an amino acid sequence of TERT may comprise or consist of a sequence of SEQ ID NOS: 6, 8, 10-13, 18, 20, 22, 24, 26, or 28, or an amino acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • a nucleic acid sequence of TERT may comprise or consist of a sequence of SEQ ID Nos: 1-5, 7, 9, 14- 17, 19, 21, 23, 25, 27, 29, 30, or 31, sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the instant ribonucleic acids may correspond to the native gene sequences coding for the above-listed TERT proteins or may correspond to variants that are made possible due to the redundancy of the genetic code, as would be understood by one of ordinary skill in the art.
  • an mRNA sequence may be synthesized as an unmodified or modified mRNA.
  • An mRNA may be modified to enhance stability and/or evade immune detection and degradation.
  • a modified mRNA may include, for example, one or more of a nucleotide modification, a nucleoside modification, a backbone modification, a sugar modification, and/or a base modification.
  • the modified nucleoside is pseudouridine or a pseudouridine analog.
  • the pseudouridine analog is N-1-methylpseudouridine.
  • the modified nucleoside is 5- methoxyuridine.
  • a modified nucleoside as used herein may comprise any of the moieties listed in Table 2. Table 2
  • an RNA e.g. an mRNA
  • an RNA may be synthesized from naturally occurring nucleosides and/or nucleoside analogs (modified nucleosides) including, but not limited to, nucleosides comprising adenosine (A), guanosine (G)) or pyrimidines (thymine (T), cytidine (C), uridine (U)), and nucleoside comprising analogues and derivatives thereof, e.g., 3 ⁇ -deoxyadenosine (cordycepin), 3 ⁇ -deoxyuridine, 3 ⁇ -deoxycytosine, 3 ⁇ -deoxyguanosine, 3 ⁇ - deoxythymine, 2 ⁇ ,3 ⁇ -dideoxynucleosides, 2 ⁇ ,3 ⁇ - dideoxyadenosine, 2 ⁇ ,3 ⁇ -dideoxyuridine, 2 ⁇ ,3 ⁇ - dideoxycytosine, 2 ⁇ ,3 ⁇ - dideoxygusine, 2 ⁇ ,3 ⁇ - dideoxyguasine, 2 ⁇ ,
  • uracil nucleosides of the mRNA are about 80%, about 90%, 95%, 99%, or 100% depleted and replaced with a uracil nucleoside analog, e.g., pseudouridine, 5-methoxyuridine, or N-1-methyl-pseudouridine.
  • an RNA may contain an RNA backbone modification.
  • a backbone modification is a modification in which the phosphates of the backbone of the nucleotides contained in the RNA are chemically modified.
  • Exemplary backbone modifications may include, but are not limited to, modifications in which the phosphodiester linkage is replaced with a member from the group consisting of peptides, methylphosphonates, methylphosphoramidates, phosphoramidates, phosphorothioates (e.g., cytidine 5 ⁇ -0-(l- thiophosphate)), boranophosphates, and/or positively charged guanidimum groups, or other means of replacing the phosphodiester linkage.
  • an RNA may contain sugar modifications.
  • a sugar modification may include but is not limited to, 2′ O-methyl sugar modifications, 2′ fluoro sugar modifications (e.g.2 ⁇ -fluororibose), 3 ⁇ amino sugar modifications, 2 ⁇ thio sugar modifications, 2 ⁇ -O-alkyl sugar modifications, 5-methylthioribose, and sugar modifications of 2 ⁇ -deoxy-2 ⁇ - fluoro-ribonucleotide (2 ⁇ -fluoro-2 ⁇ -deoxycytidine, 2 ⁇ -fluoro-2 ⁇ -deoxyuridine), 2 ⁇ -deoxy-2 ⁇ - deamine-ribonucleotide (2 ⁇ -amino-2 ⁇ -deoxycytidine, 2,-amino-2 ⁇ -deoxyuridine), 2 ⁇ -O- alkylribonucleotide, 2 ⁇ -deoxy-2 ⁇ -C-alkylribonucleotide (2 ⁇ -O-methylcytidine, 2 ⁇ - methyluridine), 2 ⁇ -C-alkylribonucleotide, and isomers thereof (2 ⁇
  • an RNA may be synthesized from one or more of the nucleotide triphosphates comprising any of the nucleosides and nucleotides disclosed herein, or any of the following nucleoside triphosphates: 2 ⁇ -Deoxyadenosine-5 ⁇ -O-(1- Thiotriphosphate), 2 ⁇ -Deoxycytidine-5 ⁇ -O-(1-Thiotriphosphate), 2 ⁇ -Deoxyguanosine-5 ⁇ -O-(1- Thiotriphosphate), 2 ⁇ -Deoxythymidine-5 ⁇ -O-(1-Thiotriphosphate), Adenosine-5 ⁇ -O-(1- Thiotriphosphate), Cytidine-5 ⁇ -O-(1-Thiotriphosphate), Guanosine-5 ⁇ -O-(1-Thiotriphosphate), Uridine-5 ⁇ -O-(1-Thiotriphosphate), 2 ⁇ ,3 ⁇ -Dideoxyadenosine-5 ⁇ -O-(1-(1- Thiotriphosphat
  • an mRNA may include the addition of a “cap” on the N- terminal (5 ⁇ ) end, and a “tail” on the C-terminal (3 ⁇ ) end.
  • the presence of the cap may provide resistance to nucleases found in eukaryotic cells.
  • the presence of a “tail” may protect the mRNA from exonuclease degradation.
  • Cap structure [0147]
  • an mRNA may include a 5 ⁇ cap structure.
  • a 5 ⁇ cap may comprise for example, a triphosphate linkage and a guanine nucleotide in which the 7-nitrogen is methylated.
  • cap structures include, but are not limited to, m7G(5 ⁇ )ppp (5 ⁇ )A, G(5 ⁇ )ppp(5 ⁇ )A, and G(5 ⁇ )ppp(5 ⁇ )G.
  • Naturally occurring cap structures comprise a 7-methyl guanosine that is linked via a triphosphate bridge to the 5 ⁇ -end of the first transcribed nucleotide, resulting in a dinucleotide cap of m7G(5 ⁇ )ppp(5 ⁇ )N, where N is any nucleoside.
  • the cap is added in the nucleus by the enzyme guanylyl transferase immediately after initiation of transcription.
  • a 5 ⁇ cap may comprise an m7(3 ⁇ OmeG)(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OmeA)pG or (CleanCap TM 3 ⁇ OMe) structure.
  • a 5 ⁇ cap may comprise a m7G(5 ⁇ )ppp(5 ⁇ )G.
  • the Anti- Reverse Cap Analog (“ARCA”) or modified ARCA is a 5 ⁇ cap in which the 2 ⁇ or 3 ⁇ OH group is replaced with -OCH3.
  • the ARCA comprises an 3′-O-Me- m7G(5′)ppp(5′)G structure.
  • the 5 ⁇ cap comprises m7G(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OmeA)pG.
  • Additional mRNA caps may include, but are not limited to, a chemical structures selected from the group consisting of m7GpppG, m7GpppA, m7GpppC; unmethylated caps (e.g., GpppG); a 44emethylated cap (e.g., m2 ⁇ 7GpppG), a trimethylated cap analog, or anti reverse cap analogs (e.g., ARCA; m7,2 ⁇ 0meGpppG, m72 ⁇ dGpppG, m7’3 ⁇ 0meGpppG, m7,3 dGpppG and their tetraphosphate derivatives) (see, e.g., Jemielity, J.
  • a suitable cap is a 7-methyl guanylate (“m7G”) linked via a triphosphate bridge to the 5 ‘-end of the first transcribed nucleotide, resulting in m7G(5 ⁇ )ppp(5 ⁇ )N, where N is any nucleoside.
  • m7G 7-methyl guanylate
  • a embodiment of a m7G cap utilized in embodiments of the disclosure is m7G(5 ⁇ )ppp(5 ⁇ )G.
  • the cap is a Cap0 structure. Cap0 structures lack a 2 ⁇ -0- methyl residue of the ribose attached to bases 1 and 2.
  • the cap is a Capl structure. Capl structures have a 2 ⁇ -0-methyl residue at base 2. In some embodiments, the cap is a Cap2 structure. Cap2 structures have a 2 ⁇ -0-methyl residue attached to both bases 2 and 3. [0150]
  • m7G cap analogs are known in the art, many of which are commercially available. These include the m7 GpppG described above, as well as the ARCA 3 ⁇ - OCH3 and 2 ⁇ -OCH3 cap analogs (Jemielity, J. et al., RNA, 9: 1108-1122 (2003)).
  • Additional cap analogs for use in embodiments of the disclosure include N7-benzylated dinucleoside tetraphosphate analogs (described in Grudzien, E. et at, RNA, 10: 1479-1487 (2004)), phosphorothioate cap analogs (described in Grudzien-Nogalska, E., et al, RNA, 13: 1745-1755 (2007)), and cap analogs (including biotinylated cap analogs) described in U.S. Patent Nos. 8,093,367 and 8,304,529, incorporated by reference herein.
  • the 5 ⁇ cap is inosine, Nl-methyl-guanosine, 2 ⁇ fluoro- guanosine, 7-deaza-guanosine, m7(3 ⁇ OmeG)(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OmeA)pG, CleanCap TM , m7(3 ⁇ OmeG)(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OmeA)pG, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azido-guanosine, Cap2, Cap4, CAP-003, or CAP-225.
  • the 5 ⁇ cap comprises or consists of an internal ribosome entry site (IRES).
  • IRES is within the 5 ⁇ UTR.
  • the 5 ⁇ cap comprises or consists of a 2A self-cleavage peptide, e.g, one or more of P2A, T2A, E2A and F2A.
  • Tail structure [0153] The presence of a “tail” may serve to protect an mRNA from exonuclease degradation. The poly-A tail is thought to stabilize natural messengers and synthetic sense RNA. Therefore, in certain embodiments a long poly-A tail can be added to an mRNA molecule thus rendering the RNA more stable.
  • Poly-A tails can be added using a variety of art-recognized techniques. For example, long poly-A tails can be added to synthetic or in vitro transcribed RNA using poly-A polymerase (Yokoe, et al. Nature Biotechnology.1996; 14: 1252-1256). A transcription vector can also encode long poly-A tails. In addition, poly-A tails can be added by transcription directly from PCR products. Poly-A may also be ligated to the 3 ⁇ end of a sense RNA with RNA ligase (see, e.g., Molecular Cloning A Laboratory Manual, 2 nd Ed., ed. By Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1991 edition)).
  • an mRNA may include a 3 ⁇ poly(A) tail structure.
  • the length of the poly-A tail may be at least about 10, 50, 100, 200, 300, 400 or at least about 500 nucleotides.
  • a poly-A tail on the 3 ⁇ terminus of an mRNA may include about 10 to 300 adenosine nucleotides (e.g., about 10 to 200 adenosine nucleotides, about 10 to 150 adenosine nucleotides, about 10 to 100 adenosine nucleotides, about 20 to 70 adenosine nucleotides, or about 20 to 60 adenosine nucleotides).
  • an mRNA may include a 3 ⁇ poly-C tail structure.
  • a poly-C tail on the 3 ⁇ terminus of mRNA may include about 10 to 200 cytosine nucleotides (e.g., about 10 to 150 cytosine nucleotides, about 10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides, about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides).
  • the poly-C tail may be added to the poly-A tail or may substitute the poly-A tail.
  • the length of the poly-A or poly C tail is associated with the stability of a modified sense mRNA and, therefore, the transcription of the protein.
  • the length of the poly-A tail may influence the half-life of a sense mRNA molecule, the length of the poly-A tail may be adjusted to modify the level of resistance of the mRNA to nucleases, thereby providing more control over the time course of polynucleotide expression and/or polypeptide production.
  • 5' an’ 3' Untranslated Regions (UTRs) [0156]
  • an mRNA may include 5 ⁇ untranslated region (UTR) and/or a 3 ⁇ UTR.
  • a 5 ⁇ UTR may include one or more elements that affect the stability or translation of an mRNA.
  • the 5 ⁇ UTR for example, may include an iron responsive element.
  • 5 ⁇ UTR may be between about 50 to about 100, or from about 50 to about 500 nucleotides in length.
  • 3 ⁇ UTR includes one or more of a poly-A signal, a binding site for proteins that may affect mRNA stability or localization, or one or more binding sites for miRNAs.
  • 3 ⁇ UTR may be between about 0 and about 50 nucleotides, or about 50 to about 100 nucleotides in length.
  • Example 3 ⁇ an’ 5 ⁇ UTR sequences may be derived from mRNAs with relatively long half-lives (e.g., globin, actin, GAPDH, tubulin, histone, or citric acid cycle enzymes) to increase the stability of the sense mRNA molecule.
  • 5 ⁇ UTR sequence may include a partial sequence of a cytomegalovirus (CMV) immediate-early 1 (IE1) gene, or a fragment thereof to improve the nuclease resistance and/or improve the half-life of the polynucleotide.
  • CMV cytomegalovirus
  • IE1 immediate-early 1
  • a UTR may improve tissue specific expression, e.g., in the lung.
  • the 3 ⁇ UTR is a mouse alpha-globin 3 ⁇ UTR.
  • the 3 ⁇ UTR comprises a sequence of SEQ ID NO: 32, or a nucleic acid sequence at least 70%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the 3 ⁇ UTR is a wild type human beta-globin 3 ⁇ UTR.
  • the 3 ⁇ UTR comprises a sequence of SEQ ID NO: 33, or a nucleic acid at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the 3 ⁇ UTR is a variant human beta-globin 3 ⁇ UTR.
  • the 3 ⁇ UTR comprises a sequence of SEQ ID NO: 34, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the 5 ⁇ UTR is a synthetic 5 ⁇ UTR.
  • the 5 ⁇ UTR comprises a sequence of SEQ ID NO: 35, or a nucleic acid at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the 5 ⁇ UTR is a human beta-globin 5 ⁇ UTR.
  • the 5 ⁇ UTR comprises a sequence of SEQ ID NO: 36, or a nucleic acid at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the UTR may be any of, or functional variants of, those described in any of PCT Application No. WO2017053297A1 and Patent No. US10519189B2, both of which are incorporated herein in their entirety.
  • Exemplary therapeutic TERT mRNA sequences [0164]
  • a TERT mRNA may refer to the full length mRNA sequence, ie.
  • the mouse TERT mRNA comprises a sequence of SEQ ID NO: 37, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the mouse TERT mRNA comprises a sequence of SEQ ID NO: 38, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the human TERT mRNA comprises a sequence of SEQ ID NO: 39, or a nucleic acid at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • the human TERT mRNA comprises a sequence of SEQ ID NO: 40, or a nucleic acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical thereto.
  • a TERT mRNA may comprise a nucleic acid sequence at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOS: 38- 40.
  • the disclosure provides compositions for the extension of telomeres in a cell, the compositions comprising a compound of the present disclosure, as described above, and a further component.
  • the further component comprises a telomerase RNA component (TERC). In some embodiments, the compositions further comprise a telomerase RNA component (TERC). In some embodiments, the compositions further comprise one or more additional components that may facilitate delivery of the RNA to cells in vitro and/or in vivo. In some embodiments, the one or more additional components comprise a nanoparticle. In some embodiments, the nanoparticle comprises a lipid. In some embodiments, the nanoparticle or the lipid comprise a coatsome-like lipid or a compound of the disclosure. In some embodiments, the nanoparticle or the lipid comprise a compound of the disclosure according to Formula I. II.
  • one or more mRNAs may be delivered to a cell or tissue via delivery vehicles.
  • a delivery vehicle may be a nanoparticle.
  • the delivery vehicle is a lipid nanoparticle (LNP) including but not limited to a nanoparticle comprising lipids and/or polymers, a liposome, a liposomal nanoparticle, a cationic lipid, or an exosome.
  • LNP lipid nanoparticle
  • liposomal nanoparticles may be characterized as microscopic vesicles having an interior aqueous space sequestered from an outer medium by a membrane of one or more bilayers.
  • the nanoparticle is a polymeric nanoparticle. In some embodiments, the nanoparticle is a metal nanoparticle. In other embodiments, the delivery vehicle comprises or consists of a recombinant virus or virus-like particle, e.g., an adenovirus, adeno-associated virus (AAV), herpesvirus, or retrovirus, e.g., lentivirus. In some embodiments, the delivery vehicle comprises or consists of a modified viral vector, e.g., an adenovirus dodecahedron or recombinant adenovirus conglomerate.
  • a recombinant virus or virus-like particle e.g., an adenovirus, adeno-associated virus (AAV), herpesvirus, or retrovirus, e.g., lentivirus.
  • the delivery vehicle comprises or consists of a modified viral vector, e.g., an adenovirus dodecahedron or recombinant adeno
  • the delivery vehicle may comprise or consist of calcium phosphate nucleotides, aptamers, cell- penetrating peptides or other vectorial tags.
  • a suitable delivery vehicle is a lipid nanoparticle (LNP)
  • Exemplary LNPs may comprise one or more different lipids and/or polymers.
  • an LNP comprises one or more of ionizable lipids, cationic lipids, structural lipids, cholesterols, and/or insulator lipids (e.g., PEGylated lipids).
  • Compositions of the disclosure may comprise one or more components that may facilitate delivery of the RNA to cells.
  • components of the composition may comprise a delivery vehicle.
  • the delivery vehicle facilitates targeting and uptake of the ribonucleic acid of a composition of the disclosure to a target cell.
  • exemplary delivery vehicles include, but are not limited to, nanoparticles, lipid nanoparticles (LNPs), liposomes, micelles, exosomes, cationic lipids and a natural or artificial lipoprotein particle.
  • Ionizable lipids [0175]
  • an LNP may comprise an ionizable lipid, e.g. SS-OP or analogs thereof. The charge of the lipid may depend on pH of the surrounding solution, making it an ionizable lipid.
  • the ionizable lipid may also be cleavable.
  • the ionizable lipid may be cationic at ranges of pH found in endosomes or lysosomes in mammalian cells.
  • An ionizable lipid may refer to any of a number of lipid species that have a net positive charge at a selected pH, such as a physiological pH.
  • an LNP may comprise an ionizable lipid as disclosed in either of WO 2010/053572 or WO 2012/170930, or variations thereof, both of which are incorporated herein by reference in their entirety.
  • an LNP for lung delivery of a TERT mRNA may comprise one or more of MC3 (((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4- (dimethylamino)butanoate), l,2-dilineoyl-3- dimethylammonium-propane (DLinDAP), DLin- MC3-DMA 4-(dimethylamino)-butanoic acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl- 10,13-nonadecadien-1-yl ester and/or cKK-E12 3,6-Bis(4-(bis(2- hydroxydodecyl)amino)butyl)piperazine-2,5-dione.
  • MC3 ((6Z,9Z,28Z,31Z)-heptatriacont
  • the LNP comprises 2,2-dilinoleyl-4-dimethylaminoethyl-[l ,3]-dioxolane (Dlin-KC2- DMA, 1) and/or (6Z,9Z,28Z,31 Z)-Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate.
  • the ionizable lipid may comprise SS-OP or analogs thereof.
  • the ionizable lipid is a compound of Formula (1): [0179]
  • R 1a and R 1b each independently represents an alkylene group having 1 to 6 carbon atoms, and may be linear or branched.
  • the alkylene group may have 1 to 4 carbon atoms, or may have 1 to 2.
  • Specific examples of the alkylene group having 1 to 6 carbon atoms include a methylene group, an ethylene group, a trimethylene group, an isopropylene group, a tetramethylene group, an isobutylene group, a pentamethylene group, and a neopentylene group.
  • R 1a and R 1b may be each independently a methylene group, an ethylene group, a trimethylene group, an isopropylene group, or a tetramethylene group, and may be an ethylene group. [0180] R 1a may be different or be the same as R 1b .
  • X a and X b are each independently an acyclic alkyl tertiary amino group having 1 to 6 carbon atoms and 1 tertiary amino group, or 2 to 5 carbon atoms, and a cyclic alkylene tertiary amino group having 1 to 2 tertiary amino groups, and/or each independently a cyclic alkylene having 2 to 5 carbon atoms and 1 to 2 tertiary amino groups and an alkylene tertiary amino group.
  • the alkyl group having 1 to 6 carbon atoms in the acyclic alkyl tertiary amino group having 1 to 6 carbon atoms and 1 tertiary amino group is branched even if it is linear.
  • the alkyl group may be annular.
  • the alkyl group may have 1 to 3 carbon atoms.
  • Specific examples of the alkyl group having 1 to 6 carbon atoms include methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, sec-butyl group, isobutyl group, tert-butyl group, pentyl group, and isopentyl group.
  • a specific structure of an acyclic alkyl tertiary amino group having 1 to 6 carbon atoms and 1 tertiary amino group is represented by X 1 .
  • R 5 of X 1 represents an alkyl group having 1 to 6 carbon atoms and may be linear, branched or cyclic.
  • the alkyl group may have 1 to 3 carbon atoms.
  • Specific examples of the alkyl group having 1 to 6 carbon atoms include methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, sec-butyl group, isobutyl group, tert-butyl group, pentyl group, and isopentyl group.
  • Neopentyl group, t-pentyl group, 1,2-dimethylpropyl group, 2- methylbutyl group, 2-methylpentyl group, 3-methylpentyl group, 2,2-dimethylbutyl group, 2,3-dimethylbutyl group, A cyclohexyl group etc. can be mentioned.
  • the number of carbon atoms in the cyclic alkylene tertiary amino group having 2 to 5 carbon atoms and 1 to 2 tertiary amino groups may be 4 to 5.
  • cyclic alkylene tertiary amino group having 2 to 5 carbon atoms and 1 to 2 tertiary amino groups include aziridylene group, azetidylene group, pyrrolidylene group, piperidylene group, imidazolidylene group, a piperazylene group, optionally a pyrrolidylene group, a piperidylene group or a piperazylene group.
  • Number is 2 to 5 carbon atoms, and specific structure of alkylene tertiary amino groups containing 1 annular tertiary amino group represented by X 2 .
  • P of X 2 is 1 or 2.
  • X 2 is a pyrrolidylene group, and when p is 2, X 2 is a piperidylene group.
  • a specific structure of a cyclic alkylene tertiary amino group having 2 to 5 carbon atoms and 2 tertiary amino groups is represented by X 3 .
  • W of X 3 is 1 or 2.
  • X 3 is an imidazolidylene group, and when w is 2, X 3 is a piperazylene group.
  • X a may be different be identical to X b .
  • R 2a and R 2b each independently represent an alkylene group or an oxydialkylene group having 8 or less carbon atoms, optionally each independently an alkylene group having 8 or less carbon atoms.
  • the alkylene group having 8 or less carbon atoms may be linear or branched but is optionally linear.
  • the number of carbon atoms contained in the alkylene group is optionally 6 or less, and optionally 4 or less.
  • alkylene group having 8 or less carbon atoms include methylene group, ethylene group, propylene group, isopropylene group, tetramethylene group, isobutylene group, pentamethylene group, hexamethylene group, heptamethylene group, octamethylene group, and the like. In some embodiments included are a methylene group, an ethylene group, a propylene group, and a tetramethylene group.
  • the oxydialkylene group having 8 or less carbon atoms refers to an alkylene group (alkylene-O-alkylene) via an ether bond, and the total number of carbon atoms of two alkylene groups is 8 or less.
  • the two alkylenes may be the same or different, but are optionally the same.
  • Specific examples of the oxydialkylene group having 8 or less carbon atoms include an oxydimethylene group, an oxydiethylene group, an oxydipropylene group, and an oxydibutylene group.
  • R 2a may be same or different and R 2b .
  • Y a and Y b are each independently an ester bond, an amide bond, a carbamate bond, an ether bond or a urea bond, optionally each independently an ester bond, an amide bond or a carbamate bond.
  • Y binding orientation of Y a and Y b are not limited, if Y a and Y b is an ester bond, optionally, -Z a -CO-–-R 2a - and -Z b -CO-O-R 2b -Structure.
  • Y a may be different or identical to Y b .
  • Z a and Z b are each independently a divalent group derived from an aromatic compound having 3 to 16 carbon atoms, having at least one aromatic ring, and optionally having a hetero atom. Represents. The number of carbon atoms contained in the aromatic compound is optionally 6 to 12, or 6 to 7.
  • the number of aromatic rings contained in the aromatic compound is optionally one.
  • the types of aromatic rings contained in the aromatic compound having 3 to 16 carbon atoms as for aromatic hydrocarbon rings, benzene ring, naphthalene ring, anthracene ring, and aromatic heterocycles as imidazole ring, pyrazole ring, oxazole ring, Isoxazole ring, thiazole ring, isothiazole ring, triazine ring, pyrrole ring, furanthiophene ring, pyrimidine ring, pyridazine ring, pyrazine ring, pyridine ring, purine ring, pteridine ring, benzimidazole ring, indole ring, benzofuran ring, quinazoline ring, phthalazine ring, quinoline ring, isoquinoline ring, coumarin ring, chromone ring,
  • the aromatic ring may have a substituent.
  • substituents include an acyl group having 2 to 4 carbon atoms, an alkoxycarbonyl group having 2 to 4 carbon atoms, a carbamoyl group having 2 to 4 carbon atoms, and 2 to 2 carbon atoms.4 acyloxy groups, acylamino groups having 2 to 4 carbon atoms, alkoxycarbonylamino groups having 2 to 4 carbon atoms, fluorine atoms, chlorine atoms, bromine atoms, iodine atoms, alkylsulfanyl groups having 1 to 4 carbon atoms, 1 carbon atom Alkylsulfonyl group having 4 to 4, arylsulfonyl group having 6 to 10 carbon atoms, nitro group, trifluoromethyl group, cyano group, alkyl group having 1 to 4 carbon atoms, ureido group having 1 to 4 carbon atoms, 1 to carbon atoms 4 alkoxy groups, ary
  • Some examples include acetyl groups, methoxycarbonyl groups, methyl carbonate groups, and the like, moyl group, acetoxy group, acetamide group, methoxycarbonylamino group, fluorine atom, chlorine atom, bromine atom, iodine atom, methylsulfanyl group, phenylsulfonyl group, nitro group, trifluoromethyl group, cyano group, methyl group, ethyl group Propyl group, isopropyl group, t-butyl group, ureido group, methoxy group, ethoxy group, propoxy group, isopropoxy group, t-butoxy group, phenyl group and phenoxy group.
  • a specific structure of Z a and Z b includes Z 1 .
  • s represents an integer of 0 to 3
  • t represents an integer of 0 to 3
  • u represents an integer of 0 to 4
  • R 4 represents a substituent.
  • S in Z 1 is optionally an integer of 0 to 1.
  • T in Z 1 is optionally an integer of 0 to 2.
  • U in Z 1 is optionally an integer of 0 to 2.
  • R 4 in Z 1 is a substituent of an aromatic ring (benzene ring) contained in an aromatic compound having 3 to 16 carbon atoms that does not inhibit the reaction in the process of synthesizing the ionizable lipid.
  • substituents examples include an acyl group having 2 to 4 carbon atoms, an alkoxycarbonyl group having 2 to 4 carbon atoms, a carbamoyl group having 2 to 4 carbon atoms, an acyloxy group having 2 to 4 carbon atoms, and an acylamino group having 2 to 4 carbon atoms, an alkoxycarbonylamino group having 2 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, alkylsulfanyl group having 1 to 4 carbon atoms, alkylsulfonyl group having 1 to 4 carbon atoms, 6 to 10 carbon atoms Arylsulfonyl group, nitro group, trifluoromethyl group, cyano group, alkyl group having 1 to 4 carbon atoms, ureido group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, aryl group having 6 to 10 carbon atoms And aryl
  • each R 4 may be the same or different.
  • Z a may be different even identical to the Z b .
  • R 3a and R 3b are each independently a residue derived from a reaction product of a fat-soluble vitamin having a hydroxyl group and succinic anhydride or glutaric anhydride, or a sterol derivative having a hydroxyl group and succinic anhydride or glutaric acid. Represents a residue derived from a reaction product with an anhydride, or an aliphatic hydrocarbon group having 12 to 22 carbon atoms, and optionally each independently a fat-soluble vitamin having a hydroxyl group and succinic anhydride or glutaric anhydride.
  • a C 12-22 aliphatic hydrocarbon group and optionally each independently an aliphatic hydrocarbon group having 12-22 carbon atoms.
  • the fat-soluble vitamin having a hydroxyl group include retinol, ergosterol, 7-dehydrocholesterol, calciferol, corcalciferol, dihydroergocalciferol, dihydrotaxolol, tocopherol, and tocotrienol.
  • the fat-soluble vitamin having a hydroxyl group is optionally tocopherol.
  • Examples of the sterol derivative having a hydroxyl group include cholesterol, cholestanol, stigmasterol, ⁇ -sitosterol, lanosterol, ergosterol and the like, optionally cholesterol or cholestanol.
  • the aliphatic hydrocarbon group having 12 to 22 carbon atoms may be linear or branched.
  • the aliphatic hydrocarbon group may be saturated or unsaturated. In the case of an unsaturated aliphatic hydrocarbon group, the number of unsaturated bonds contained in the aliphatic hydrocarbon group is usually 1 to 6, optionally 1 to 3, or 1 to 2.
  • Unsaturated bonds include carbon-carbon double bonds and carbon-carbon triple bonds.
  • the number of carbon atoms contained in the aliphatic hydrocarbon group is optionally 13 to 19, or 13 to 17.
  • the aliphatic hydrocarbon group includes an alkyl group, an alkenyl group, an alkynyl group and the like, and optionally includes an alkyl group or an alkenyl group.
  • aliphatic hydrocarbon group having 12 to 22 carbon atoms include dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, icosyl, heicosyl, docosyl, Dodecenyl group, tridecenyl group, tetradecenyl group, pentadecenyl group, hexadecenyl group, heptadecenyl group, octadecenyl group, nonadecenyl group, icocenyl group, henicocenyl group, dococenyl group, dodecadienyl group, tridecadienyl group, tetradecadienyl group, pentadecadienyl group Group, hexadecadienyl group,
  • the aliphatic hydrocarbon group having 12 to 22 carbon atoms is optionally a tridecyl group, a pentadecyl group, a heptadecyl group, a nonadecyl group, a heptadecenyl group, a heptadecadienyl group, or a 1-hexylnonyl group, or a tridecyl group, A heptadecyl group, a heptadecenyl group, and a heptadecadienyl group.
  • the aliphatic hydrocarbon group having 12 to 22 carbon atoms represented by R 3a and R 3b is derived from a fatty acid.
  • the carbonyl carbon derived from the fatty acid is contained in —CO—O— in the formula (1).
  • Specific examples of the aliphatic hydrocarbon group include a heptadecenyl group when linoleic acid is used as the fatty acid, and a heptadecenyl group when oleic acid is used as the fatty acid.
  • R 3a may be different be the same as R 3b .
  • R 1a is the same as R 1b
  • X a is the same as X b
  • R 2a is the same as R 2b
  • Y a is the same as Y b
  • Z a is identical to the Z b
  • R 3a is the same as R 3b .
  • Preferable examples of the ionizable lipid represented by the formula (1) include the following ionizable lipids: Ionizable lipid (1-1); R 1a and R 1b are each independently an alkylene group having 1 to 6 carbon atoms (eg, methylene group, ethylene group); X a and X b are each independently an acyclic alkyl tertiary amino group having 1 to 6 carbon atoms and 1 tertiary amino group (eg, —N (CH 3 ) —), Or a cyclic alkylene tertiary amino group having 2 to 5 carbon atoms and 1 to 2 tertiary amino groups (eg, piperidylene group); R 2a and R 2b are each independently an alkylene group having 8 or less carbon atoms (eg, methylene group, ethylene group, propylene group); Y a and Y b are each independently an ester bond or an amide bond; Z a and Z b are each
  • R 3a and R 3b are each independently a residue derived from a reaction product of a fat-soluble vitamin having a hydroxyl group (eg, tocopherol) and succinic anhydride or glutaric anhydride, or an aliphatic group having 12 to 22 carbon atoms A hydrocarbon group (eg, heptadecenyl group, heptadecadienyl group, 1-hexylnonyl group); [0214] Ionizable lipid (1-2); R 1a and R 1b are each independently an alkylene group having 1 to 4 carbon atoms (eg, methylene group, ethylene group); X a and X b are each independently an acyclic alkyl tertiary amino group having 1 to 3 carbon atoms and 1 tertiary amino group (eg, —N (CH 3 )
  • R 1a and R 1b are each independently an alkylene group having 1 to 2 carbon atoms (eg, methylene group, ethylene group);
  • X a and X b are each independently X 1 : wherein R 5 is an alkyl group having 1 to 3 carbon atoms (eg, a methyl group)), or X 2 : wherein p is 1 or 2),
  • R 2a and R 2b are each independently an alkylene group having 4 or less carbon atoms (eg, methylene group, ethylene group, propylene group);
  • Y a and Y b are each independently an ester bond or an amide bond;
  • Z a and Z b are each independently Z 1 : wherein s is an integer from 0 to 1, t is an integer from 0 to 2, u is an integer from 0 to 2 (optionally 0), and (R 4 )u are each independently represents a substituent.
  • R 3a and R 3b are each independently a residue derived from a reaction product of a fat-soluble vitamin having a hydroxyl group (eg, tocopherol) and succinic anhydride, or an aliphatic hydrocarbon group having 13 to 17 carbon atoms (eg, Heptadecenyl group, heptadecadienyl group, 1-hexylnonyl group);
  • a fat-soluble vitamin having a hydroxyl group eg, tocopherol
  • succinic anhydride eg, an aliphatic hydrocarbon group having 13 to 17 carbon atoms (eg, Heptadecenyl group, heptadecadienyl group, 1-hexylnonyl group);
  • Specific examples of the ionizable lipid according to Formula 1 of the present disclosure include the following O-Ph-P3C1, O-Ph-P4C1, O-Ph-P4C2, O-Bn-P4C2, E
  • the delivery vehicle is an LNP capable of transfecting at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of a population of lung cells wherein the ionizable lipid is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% of the molar percentage of the LNP.
  • the ionizable lipid is no more than 20%, no more than 30%, no more than 40%, no more than 50%, no more than 60%, no more than 70%, or no more than 90% of the molar percentage of the LNP.
  • Example ionizable lipids include, but are not limited to: (15Z,18Z)—N,N-dimethyl-6-(9Z,12Z)-octadeca-9,12-dien-1-yl)tetracosa- 15,18-dien-1-amine (HGT5000), (15Z,18Z)—N,N-dimethyl-6-((9Z,12Z)-octadeca-9,12-dien- 1-yl)tetracosa-4,15,18-trien-1-amine (HGT5001), and (15Z,18Z)—N,N-dimethyl-6- ((9Z,12Z)-octadeca-9,12-dien-1-yl)tetracosa-5,15,18-trien-1-amine (HGT5002).
  • Lipids having the structure of Formula I are shown in Table 5 below.
  • SS-OP is also named 0-Ph-P4C2.
  • the term “SS-OP analog” as used herein refers to a compound of Formula I. Table 5: Nomenclature of Lipids
  • a lipid nanoparticle (LNP) of the disclosure comprises a cationic lipid, e.g. DOTAP or variations thereof.
  • the cationic lipid may be a “permanent cationic lipid.”
  • the term cationic lipid may be cationic in pH ranges found in mammalian physiological environments such as blood or interstitial fluids.
  • Cationic lipids may be composed of a cationic amine moiety and a lipid moiety, and the cationic amine moiety and a polyanion nucleic acid may interact to form a positively charged liposome or lipid membrane structure. Thus, uptake into cells may be promoted and nucleic acids delivered into cells.
  • the cationic lipid may selected from one or more of 1,2- dioleoyl-3-trimethylammonium-propane (DOTAP), N,N-distearyl-N,N-dimethylarnmonium bromide (DABB), or 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (EPC).
  • DOTAP 1,2- dioleoyl-3-trimethylammonium-propane
  • DABB N,N-distearyl-N,N-dimethylarnmonium bromide
  • EPC 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine
  • an LNP comprises a ionizable lipid wherein the ionizable lipid is one or more of N-[l-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 5- carboxyspermylglycinedioctadecylamide (DOGS), 2,3-dioleyloxy-N-[2(spermine- carboxamido)ethyl]-N,N-dimethyl-1-propanaminium (DOSPA), 1,2-Dioleoyl-3- Dimethylammonium-Propane (DODAP), 11,2-distearyloxy-N,N-dimethyl-3-aminopropane (DSDMA), 1,2-dioleyloxy-N,N-dimethyl-3-aminopropane (DODMA), 1,2-dilinoleyloxy- N,N-dimethyl-3-aminopropane (DLinD
  • a cationic lipid refers to a cationic cholesterol lipid.
  • an LNP comprises imidazole cholesterol ester (ICE).
  • an ICE structure is substantially similar to: [0222]
  • an LNP comprises 25-Hydroxycholesterol (25 OH Chol).
  • 25 OH Chol structure is substantially similar to: [0223]
  • an LNP comprises 20 ⁇ -hydroxycholesterol 5-cholestene-3 ⁇ .
  • the 20 ⁇ -hydroxycholesterol 5-cholestene-3 ⁇ (also known as 20 ⁇ -diol or 20 ⁇ chol structure) is substantially similar to: [0225]
  • a cationic lipid refers to dimethyldioctadecylammonium bromide (DDAB).
  • DDAB dimethyldioctadecylammonium bromide
  • DDAB dimethyldioctadecylammonium bromide
  • DDAB dimethyldioctadecylammonium bromide
  • the LNP comprises a structural lipid.
  • structural lipids are lipids that contribute a physical or chemical property to the LNP that is in addition to, or independent of, electrical charge.
  • structural lipids may tend to have a shape, size, rigidity, hydrophobicity, or other property that increases the therapeutic utility of the LNP, such as, for example, by increasing its stability, half-life, deformability, transfection efficiency, tropism, thermostability, resistance to aggregation, membrane fluidity, or other parameter.
  • structural lipids are neutral in charge, either due to lacking charged moieties, or due to being zwitterionic with balanced charges summing to zero net charge.
  • an LNP may comprise a structural lipid selected from one more of: 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), glycerol- monooleate (GMO), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane
  • DOPE 1,2-di
  • an LNP may include one or more phosphatidyl lipids, for example, the phosphatidyl compounds (e.g., phosphatidylglycerol, phosphatidylcholine, phosphatidylserine and phosphatidylethanolamine).
  • an LNP may comprise sphingolipids, for example but not limited to, sphingosine, ceramide, sphingomyelin, cerebroside and ganglioside.
  • the aforementioned “structural” lipids contribute to the stability and/or specificity of the LNP composition.
  • an LNP may comprise one or more cholesterol-based lipids.
  • a cholesterol-based lipid may include but is not limited to: PEGylated cholesterol, DC-Choi (N,N-dimethyl-N-ethylcarboxamidocholesterol), l,4-bis(3-N-oleylamino-propyl)piperazine.
  • PEGylated Lipids [0230] In some embodiments of the disclosure, an LNP may comprise one or more PEGylated lipids.
  • PEG-modified phospholipids and derivatized lipids such as derivatized ceramides (PEG-CER), including N-Octanoyl- Sphingosine-l-[Succinyl(Methoxy Polyethylene Glycol)-2000] (C8 PEG-2000 ceramide) is contemplated by the present disclosure in combination with one or more of the ionizable and/or other lipids.
  • PEGylated lipids comprise PEG-ceramides having shorter acyl chains (e.g., C14 or C18).
  • the PEGylated lipid DSPE-PEG- Maleimide-Lectin may be used.
  • PEG-modified lipids include, but are not limited to, a polyethylene glycol chain of up to 5 kDa in length covalently attached to a lipid with alkyl chain(s) of C6-C2o length.
  • the addition of PEGylated lipids may prevent complex aggregation and increase circulation lifetime to facilitate the delivery of the liposome encapsulated mRNA to the target cell.
  • a lipid nanoparticle formulation may comprise, consist essentially of or consist of any of those described in U.S.
  • an LNP may comprise an ionizable lipid, e.g. an SS-OP or SS-OP analog in a molar percentage of about 20, about 25, about 30, about 35, about 40, about 45, about 55, or about 60 relative to the total lipid; and a cationic lipid, e.g. DOTAP, ICE, DDAB or a cationic cholesterol lipid, in a molar percentage of about 15, about 20, about 25, about 30, about 35, about 40, about 45, or about 50 relative to the total lipid.
  • the LNP comprises the cationic lipid at a molar percentage of between about 25% and about 35%.
  • the LNP comprises the cationic lipid at a molar percentage of about 30%.
  • the LNP comprises a structural lipid.
  • the structural lipid is DOPC.
  • the LNP comprises DOPC in a molar ration of about 1%, about 2%, about 3%, about 4%, or about 5% of the total lipid.
  • the LNP is substantially free of structural lipids and/or comprises at most 1% structural lipids.
  • the LNP comprises cholesterol. In some embodiments, the LNP comprises a molar percentage of about 20% to about 40% cholesterol relative to the total lipid.
  • the LNP is substantially free of cholesterol.
  • the LNP comprises an insulator lipid.
  • the LNP comprises an insulator lipid in a molar ratio of about 0.1% to about 2%.
  • the LNP comprises an insulator lipid in a molar ratio of about 0.5% to about 1.5%.
  • the LNP is substantially free of insulator lipids.
  • Polymer nanoparticles [0238] In some embodiments, a suitable delivery vehicle is formulated using a polymer as a carrier, alone or in combination with other carriers including various lipids described herein.
  • liposomal delivery vehicles also encompass polymer containing nanoparticles.
  • Suitable polymers may include, for example, polyacrylates, polyalkycyanoacrylates, polylactide, polylactide-polyglycolide copolymers, polycaprolactones, dextran, albumin, gelatin, alginate, collagen, chitosan, cyclodextrins, protamine, polyethylene glycol (PEG)-modified (PEGylated) protamine, poly-D-lysine (PLL), PEGylated PLL and polyethylenimine (PEI).
  • PEI When PEI is present, it may be linear or branched PEI of a molecular weight ranging from 10 to 40 kDA, e.g., 25 kDa branched PEI (Sigma #408727). In some embodiments the PEGylated lipid is 14:0 PEG2000 PE and/or DMG- PEG2000. Lung targeting [0239]
  • the delivery vehicles disclosed herein preferentially target the lung. In various embodiments, the delivery vehicles may deliver and/or transfect a polynucleotide, e.g. an mRNA to lung cells 10, 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , or 10 10 -fold more effectively compared to the liver.
  • a polynucleotide e.g. an mRNA to lung cells 10, 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , or 10 10
  • LNP compositions as provided herein preferentially deliver to and/or transfects a polynucleotide, e.g. an RNA, to the lung compared to liver.
  • a polynucleotide e.g. an RNA
  • the lipid composition of a delivery vehicle enhances delivery to the lung relative to other lipid compositions known in the art.
  • the lipid composition of a delivery vehicle enhances delivery to the lung relative to other lipid compositions.
  • the presence or level of cholesterol enhances delivery of a delivery vehicle, e.g. an LNP or extracellular vesicle to the lung.
  • a delivery vehicle comprises an organ-specific targeting ligand to enhance delivery to a particular organ, e.g. the lung III.
  • organ-specific targeting ligand to enhance delivery to a particular organ, e.g. the lung III.
  • mRNA and nanoparticle delivery vehicle compositions [0241] The methods of synthesis of mRNA and lipid nanoparticles (LNPs) are well established. Synthetic mRNAs, e.g., comprising a 5 ⁇ cap, 5 ⁇ and 3 ⁇ UTRs coding sequence, and a poly-A tail, may be synthesized from modified and unmodified nucleotides by in vitro transcription of a DNA template using an RNA polymerase, for example T7 RNA polymerase.
  • RNA polymerase for example T7 RNA polymerase.
  • the DNA template may be generated, for example, by PCR or plasmid amplification and restriction digest, followed by purification.
  • Lipid nanoparticles (LNPs), liposomes, or polymer nanoparticle delivery vehicles carrying mRNA may be produced, for example, by mixing the lipids or polymers in an organic solvent, e.g., ethanol, with one or more mRNAs in an aqueous buffer, and then subject to buffer exchange and concentration.
  • the LNP, liposome, or polymer nanoparticle delivery vehicle may be produced using a microfluidic device to rapidly mix reagents and form monodisperse particles of controlled size.
  • the microfluidic mixer could be a staggered herringbone mixer (SHM).
  • the microfluidic mixer could be produce by the NanoAsssemblr made by Precision Nanosystems (PNI).
  • the LNP, liposome, or polymer nanoparticle delivery vehicle may be produced by a T-mixer.
  • the LNP, liposome, or polymer nanoparticle may encapsulate an mRNA and/or associate with one or more mRNAs through electrostatic interactions.
  • the buffer exchange and concentration of the LNP, liposome, or polymer nanoparticle may be performed by tangential flow filtration.
  • the lipid nanoparticle particles (LNP) formulations provided herein are capable of transfecting at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of a population of lung cells.
  • the form of the lipid membrane structure of the present disclosure is not particularly limited.
  • lipid of the present disclosure is dispersed in an aqueous solvent
  • liposomes for example, monolayer liposomes, multilamellar liposomes, etc.
  • spherical micelles for example, string micelles, lipid nanoparticles (LNPs) or unspecified layered structures.
  • LNPs lipid nanoparticles
  • the lipid membrane structure of the present disclosure may further contain other component.
  • lipids examples include lipids (phospholipids (such as phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, phosphatidylglycerol, phosphatidylcholine), glycolipids, peptide lipids, cholesterol, ionizable lipids, cationic lipids, PEGylated lipids, etc.), surfactants (eg 3-[(3-cholamidopropyl) dimethylammonio] propane sulfonate, cholic acid sodium salt, octyl glycoside, ND-gluco -N- methylalkanamides), polyethylene glycol, proteins and the like.
  • lipids phospholipids (such as phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, phosphatidylglycerol, phosphatidyl
  • the content of the other constituents in the lipid membrane structure of the present disclosure is usually 5 to 95 mol%, optionally 10 to 90 mol%, or 30 to 80 mol%.
  • the lipid membrane structure of the present disclosure is prepared by dispersing the lipids of the present disclosure and other components (lipids, etc.) in a suitable solvent or dispersion medium, for example, an aqueous solvent or an alcoholic solvent, and if necessary, tissue It can be prepared by performing an operation that induces crystallization.
  • Examples of the “operation for inducing organization” include an ethanol dilution method using a microchannel or a vortex, a simple hydration method, an ultrasonic treatment, a heating, a vortex, an ether injection method, a French press method, and a cholic acid method. Examples thereof include, but are not limited to, methods known per se such as Ca 2+ fusion method, freeze-thaw method, and reverse phase evaporation method.
  • the nucleic acid can be introduced into the cell in vivo and / or in vitro by encapsulating the nucleic acid in the lipid membrane structure containing the ionizable lipid of the present disclosure and bringing it into contact with the cell.
  • the present disclosure provides a nucleic acid introduction agent comprising the ionizable lipid or lipid membrane structure of the present disclosure.
  • the nucleic acid introduction agent of the present disclosure can introduce any nucleic acid into cells.
  • the nucleic acid include, but are not limited to, DNA, RNA, RNA chimeric nucleic acid, DNA / RNA hybrid, and the like.
  • the nucleic acid can be any one of 1 to 3 strands, but is optionally single strand or double strand.
  • Nucleic acids may be other types of nucleotides that are N-glycosides of purine or pyrimidine bases, or other oligomers having a non-nucleotide backbone (e.g., commercially available peptide nucleic acids (PNA), etc.) or other oligomers with special linkages.
  • the oligomer may contain nucleotides having a configuration that allows base pairing or base attachment as found in DNA or RNA.
  • nucleic acid may be substituted with, for example, a known modified nucleic acid, a labeled nucleic acid, a capped nucleic acid, a methylated nucleic acid, or one or more natural nucleotides known in the art, intramolecular nucleotide modified nucleic acids, nucleic acids with uncharged bonds (e.g., methyl sulfonate, phosphotriester, phosphoramidate, carbamate, etc.), charged bonds or sulfur containing bonds (eg phosphorothioate), side chain groups such as proteins (e.g., nucleases, nuclease inhibitors, toxins, antibodies, signal peptides, poly-L- lysine, etc.) and sugars (eg, monosaccharides), nucleic acids and nucleic acids with intercurrent compounds (eg, acridine, psoralen, etc.), nucleic acids containing chelate compounds (eg, metals,
  • RNA examples include plasmid DNA, cDNA, antisense DNA, chromosomal DNA, PAC, BAC, and CpG oligo, optionally plasmid DNA, cDNA, and antisense DNA, or plasmid DNA.
  • Circular DNA such as plasmid DNA can be appropriately digested with a restriction enzyme or the like and used as linear DNA.
  • the type of RNA that can be used in the present disclosure is not particularly limited, and can be appropriately selected depending on the purpose of use.
  • siRNA, miRNA, shRNA, antisense RNA messenger RNA (mRNA), single-stranded RNA genome, double-stranded RNA genome, RNA replicon, transfer RNA, ribosomal RNA, etc.
  • siRNA, miRNA, shRNA, mRNA, antisense RNA, RNA replicon optionally siRNA, miRNA, shRNA, mRNA, antisense RNA, RNA replicon.
  • the nucleic acid used in the present disclosure is optionally purified by a method commonly used by those skilled in the art.
  • the nucleic acid-introducing agent of the present disclosure encapsulating nucleic acid can be administered in vivo for the purpose of, for example, prevention and / or treatment of diseases.
  • the nucleic acid used in the present disclosure is optionally a nucleic acid having preventive and / or therapeutic activity against a given disease (prophylactic / therapeutic nucleic acid).
  • examples of such nucleic acids include nucleic acids used for so- called gene therapy.
  • the aqueous solution of nucleic acid and the ethanol solution of the components of the lipid membrane structure of the present disclosure are vigorously mixed by vortex or microchannel, etc. Is diluted with an appropriate buffer.
  • the components (lipids, etc.) of the lipid membrane structure of the present disclosure are dissolved in an appropriate organic solvent, the solution is placed in a glass container, and the solvent is retained by drying under reduced pressure and left to obtain a lipid film.
  • an aqueous solution of nucleic acid is added and hydrated, followed by sonication with a sonicator.
  • the present disclosure also provides the above lipid membrane structure in which such a nucleic acid is encapsulated.
  • An example of a lipid membrane structure in which a nucleic acid is encapsulated is LNP encapsulated in a nucleic acid by forming an electrostatic complex between the nucleic acid and a ionizable lipid.
  • This LNP can be used as a drug delivery system for selectively delivering a nucleic acid or the like into a specific cell.
  • a DNA vaccine by introducing an antigen gene into a dendritic cell, a gene therapy drug for a tumor, RNA It is useful for nucleic acid drugs that suppress the expression of target genes using interference.
  • the particle diameter of the lipid membrane structure of the present disclosure encapsulating nucleic acid is not particularly limited, but is optionally 10 nm to 500 nm, or 20 nm to 200 nm.
  • the particle diameter can be measured using a particle size distribution measuring apparatus such as Zetasizer Nano (Malvern).
  • the particle diameter of the lipid membrane structure can be appropriately adjusted according to the method for preparing the lipid membrane structure.
  • the surface potential (zeta potential) of the lipid membrane structure of the present disclosure encapsulating nucleic acid is not particularly limited, but may be ⁇ 60 to +60 mV, ⁇ 45 to 45 mV, ⁇ 30 to +30 mV, ⁇ 15 to +15 mV, or ⁇ 10 to +10 mV.
  • the zeta potential of the lipid membrane structure may be positive (>0 mV), +5mV to + 60mV, +30mM to + 45mV, or +10mV to + 45mV.
  • particles having a positive surface potential have been mainly used.
  • the surface charge can be measured by using a zeta potential measuring device such as Zetasizer Nano.
  • the surface charge of the lipid membrane structure can be adjusted by the composition of the components of the lipid membrane structure.
  • the lipid membrane surface pKa (hereinafter referred to as Liposomal pKa) of the lipid membrane structure of the present disclosure is not particularly limited, but may have a pKa of 5.5 to 7.2, or a pKa of 6.0. to 6.8.
  • Liposomal pKa is used as an index indicating that the lipid membrane structure taken up by endocytosis is susceptible to protonation of the lipid membrane structure in a weakly acidic environment within the endosome.
  • Liposomal pKa can be adjusted by the composition of the components of the lipid membrane structure.
  • the hemolysis activity (membrane fusion ability) of a lipid membrane structure of the present disclosure is not particularly limited, but may have no hemolysis activity (less than 5%) at physiological pH (pH 7.4), and may be endosomal.
  • the higher the hemolysis activity the more efficiently the nucleic acid can be delivered into the cytoplasm.
  • the hemolysis activity is present at physiological pH, the nucleic acid will be delivered to unintended cells during residence in the blood, resulting in decreased target-directedness and toxicity. Therefore, it is preferable to have hemolysis activity only in the endosomal environment as described above.
  • the hemolysis activity can be adjusted by the composition of the components of the lipid membrane structure.
  • the encapsulated nucleic acid can be introduced into the cell.
  • the cell may be a cultured cell line containing cancer cells, a cell isolated from an individual or tissue, or a tissue or tissue piece of cell. Further, the cells may be adherent cells or non-adherent cells.
  • the step of bringing the lipid membrane structure of the present disclosure encapsulating nucleic acid into contact with cells in vitro will be specifically described below.
  • Cells are suspended in an appropriate medium several days before contact with the lipid membrane structure and cultured under appropriate conditions.
  • the culture medium at the time of the contact may be a serum-containing medium or a serum-free medium, but the serum concentration in the medium may be 30% by weight or less, more may be 20% by weight or less. If the medium contains excessive protein such as serum, the contact between the lipid membrane structure and the cell may be inhibited.
  • the cell density at the time of the contact is not particularly limited and can be appropriately set in consideration of the cell type, but is usually in the range of 1 ⁇ 10 4 to 1 ⁇ 10 7 cells/mL.
  • a suspension of the lipid membrane structure of the present disclosure in which the above-described nucleic acid is encapsulated is added to the cells thus prepared.
  • the addition amount of the suspension is not particularly limited, and can be appropriately set in consideration of the number of cells and the like.
  • the concentration of the lipid membrane structure at the time of contacting the cell is not particularly limited as long as the introduction of the target nucleic acid into the cell can be achieved, but the lipid concentration is usually 1 to 100 nmol / mL, and may be 0.1 to 10 ⁇ g / mL.
  • the temperature is usually about 37 ° C.
  • the humidity is about 95%
  • the CO 2 concentration is about 5%.
  • the culture time can be appropriately set in consideration of conditions such as the type of cells used, but may be in the range of 0.1 to 76 hours, or in the range of 0.2 to 24 hours, and may be 0..5-12 hours. If the culture time is too short, the nucleic acid is not sufficiently introduced into the cells, and if the culture time is too long, the cells may be weakened. [0267]
  • the nucleic acid is introduced into the cells by the above-described culture.
  • the medium may be replaced with a fresh medium, or the fresh medium is added to the medium and the cultivation is further continued.
  • the lipid membrane structure of the present disclosure may further contain other components in addition to the ionizable lipid of the present disclosure.
  • the other components include lipids (phospholipids (such as phosphatidylinositol, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, phosphatidylglycerol, phosphatidylcholine), glycolipids, peptide lipids, cholesterol, ionizable lipids other than cationic lipids, PEG lipids, etc.), surfactants (eg 3-[(3-cholamidopropyl) dimethylammonio] propane sulfonate, cholic acid sodium salt, octyl glycoside, ND-gluco -N-methylalkanamides), polyethylene glycol, proteins and the like.
  • lipids phospholipids (such as phosphatidylinositol, phosphatidylethanolamine, phosphatidy
  • the lipid membrane structure of the present disclosure is prepared by dispersing the ionizable lipid of the present disclosure and other components (lipids, etc.) in a suitable solvent or dispersion medium, for example, an aqueous solvent or an alcoholic solvent, and if necessary, tissue. It can be prepared by performing an operation that induces crystallization.
  • a suitable solvent or dispersion medium for example, an aqueous solvent or an alcoholic solvent, and if necessary, tissue. It can be prepared by performing an operation that induces crystallization.
  • Examples of the “operation for inducing organization” include an ethanol dilution method using a microchannel or a vortex, a simple hydration method, an ultrasonic treatment, a heating, a vortex, an ether injection method, a French press method, and a cholic acid method.
  • the nucleic acid can be introduced into the cell in vivo and / or in vitro by encapsulating the nucleic acid in the lipid membrane structure containing the ionizable lipid of the present disclosure and bringing it into contact with the cell. Therefore, the present disclosure provides a nucleic acid introduction agent comprising the ionizable lipid or lipid membrane structure of the present disclosure.
  • the nucleic acid introduction agent of the present disclosure can introduce any nucleic acid into cells.
  • nucleic acid examples include, but are not limited to, DNA, RNA, RNA chimeric nucleic acid, DNA / RNA hybrid, and the like.
  • the nucleic acid can be any one of 1 to 3 strands, but may be single strand or double strand.
  • Nucleic acids may be other types of nucleotides that are N-glycosides of purine or pyrimidine bases, or other oligomers having a non-nucleotide backbone (eg, commercially available peptide nucleic acids (PNA), etc.) or other oligomers with special linkages.
  • the oligomer may contain nucleotides having a configuration that allows base pairing or base attachment as found in DNA or RNA.
  • RNA Ribonucleic acid
  • the nucleic acid used in the present disclosure may be purified by a method commonly used by those skilled in the art.
  • the nucleic acid-introducing agent of the present disclosure encapsulating nucleic acid can be administered in vivo for the purpose of, for example, prevention and / or treatment of diseases.
  • the nucleic acid used in the present disclosure may be a nucleic acid having preventive andat/or therapeutic activity against a given disease (prophylactic / therapeutic nucleic acid). Examples of such nucleic acids include nucleic acids used for so- called gene therapy.
  • Methods of treatment refer to the treatment of fibrotic disease and/or lung disease and/or lung fibrosis in a subject in need thereof by administration of a composition comprising one or more TERT mRNA sequences.
  • compositions and methods of the disclosure may be used for the treatment of fibrotic conditions, including fibrosis.
  • compositions and/or methods of use of compositions of the disclosure intended for treatment of fibrotic conditions, including fibrosis induce TERT expression or increase TERT activity in a lung cell.
  • compositions and/or methods of use of compositions of the disclosure intended for treatment of fibrotic conditions, including fibrosis do not induce cellular, tissue or systemic toxicity.
  • Compositions may be administered systemically, e.g., intravenously.
  • telomerase reverse transcriptase mRNA
  • a TERT mRNA is administered in a dose of about 0.001 mg/kg per the subject’s body weight to about 2.0 mg/kg per the subject’s body weight to a subject in need thereof.
  • a TERT mRNA is administered to a subject in need thereof in a dose of about 0.01 mg/kg; in some embodiments in a dose of about 0.025 mg/kg; in some embodiments in a dose of about 0.05 mg/kg; in some embodiments in a dose of about 0.075 mg/kg; in some embodiments in a dose of about 0.1 mg/kg; in some embodiments in a dose of about 0.125 mg/kg; in some embodiments in a dose of about 0.150 mg/kg; in some embodiments in a dose of about 0.175 mg/kg; in some embodiments in a dose of about 0.2 mg/kg; in some embodiments in a dose of about 0.5 mg/kg; in some embodiments in a dose of about 0.75 mg/kg; in some embodiments in a dose of about 1.0 mg/kg; in some embodiments, in a dose of about 1.25 mg/kg; in some embodiment in a dose of about 1.5 mg/kg; or in some embodiment in a dose of about 2.0 mg
  • the TERT mRNA is administered to a subject in need thereof in a dose of 0.1 mg/kg. In some embodiments the TERT mRNA is administered to a subject in need thereof in a dose of 0.125 mg/kg. [0278] In some embodiments the TERT mRNA is administered to a subject in need thereof in a single dose. In some embodiments the TERT mRNA is administered to a subject in need thereof two, three, four, or five or more times. In some embodiments, the TERT mRNA is administered twice a week, every week, every two weeks, every four weeks, every six weeks, every twelve weeks, or every fifteen weeks.
  • the TERT mRNA is administered every month, every two months, every three months, every six months, once a year, on an ongoing basis, or as determined by their physician.
  • TERT mRNA co-therapies [0279] In some embodiments, co-administration of a TERT mRNA may be combined with other anti-fibrotic drugs used in the treatment of fibrotic diseases and/or lung diseases. Drugs that may be used include, but are not limited to nintedanib, pirfenidone, prednisone, azathioprine, cyclophosphamide, mycophenolate mofetil, Pamrevlumab, and N-acetylcysteine.
  • a TERT mRNA may be delivered orally, subcutaneously, intravenously, intranasally, intradermally, transdermally, intraperitoneally, intramuscularly, intrapulmonarily, vaginally, rectally, or intraocularly.
  • a TERT mRNA may be administered intravenously or through inhalation.
  • Subjects and Treatment [0281] The methods of treatment described herein are useful for the treatment of lung disease and/or lung fibrosis in a subject in need thereof.
  • Lung and lung fibrotic diseases may include, but are not limited to pulmonary fibrosis, lung cancer, familial pulmonary fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis associated with dyskeratosis congenita, an interstitial lung disease (ILD), pneumonia, interstitial pneumonia, tuberculosis, bronchitis, emphysema, lung cancer, chronic obstructive pulmonary disease (COPD), aging-associated fibrosis, pulmonary hypertension, asthma, and cystic fibrosis.
  • a subject in need of the combination treatments described herein is a subject with a genetic disorder or mutation in telomerase reverse transcriptase (TERT).
  • a subject in need of treatments described herein is a subject with a genetic disorder or mutation in telomerase reverse transcriptase (TERT).
  • TERT telomerase reverse transcriptase
  • the subject has no symptoms of lung disease and/or lung fibrosis.
  • the subject has symptoms and the treatment completely or partially ameliorates the symptoms.
  • the treatment slows progression of the symptoms.
  • the subject is human.
  • efficacy of the treatment may be measured by lung or pulmonary function may be performed by methods including not limited to: spirometry, body plethysmography, methacholine inhalation challenge, six-minute walk test, exhaled nitric oxide test, arterial blood gas test, lung volume test, lung diffusion capacity, cardiopulmonary exercise test, oximetry with ambulation, respiratory muscle strength test, altitude simulation tests, exercise challenge (with spirometry before and after), shunt study (100% O2), forced expiratory volume (FEV1), forced vital capacity (FVC), and maximal voluntary volume (MVV).
  • FEV1 forced expiratory volume
  • FVC forced vital capacity
  • MVV maximal voluntary volume
  • administration of a TERT mRNA reduces fibrotic tissue in a subject by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or at least 100% over the treatment period and/or after the treatment period.
  • administration of a TERT mRNA stops or slows the increase in fibrotic tissue over time relative to a subject without treatment.
  • the administration of a TERT mRNA slows the increase in amount of fibrotic tissue in a subject by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or at least 100% over the treatment period and/or after the treatment period.
  • administration of a TERT mRNA increases lung function relative to a subject without treatment.
  • the administration of a TERT mRNA increases lung function in a subject by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% over the treatment period and/or after the treatment period.
  • administration of a TERT mRNA extends survival relative to a subject without treatment. In some embodiments, administration of a TERT mRNA extends lung transplant-free survival relative to a subject without treatment. In some embodiments, the administration of a TERT mRNA extends survival of a subject by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, at least 100%, at least 200%, at least 300%, at least 400%, at least 500%, at least 1000%, over the treatment period and/or after the treatment period.
  • a composition comprising a TERT mRNA includes an excipient, or carrier, e.g., an aqueous carrier.
  • aqueous carriers can be used, e.g., buffered saline.
  • compositions may contain pharmaceutically acceptable auxiliary substances as those required to approximate physiological conditions such as pH and buffering agents, toxicity countering agents, e.g., sodium acetate, sodium chloride, sodium citrate, potassium chloride, calcium chloride, and sodium lactate.
  • toxicity countering agents e.g., sodium acetate, sodium chloride, sodium citrate, potassium chloride, calcium chloride, and sodium lactate.
  • the pharmaceutical composition comprises 10 mM sodium citrate buffered to pH 6.4.
  • the composition may contain a cryoprotectant, e.g., glycerol, ethylene glycol, sucrose, propylene glycol, or dimethylsulfoxide (DMSO).
  • a cryoprotectant e.g., glycerol, ethylene glycol, sucrose, propylene glycol, or dimethylsulfoxide (DMSO).
  • the concentration of active agent in these formulations can vary and are selected based on fluid volumes, viscosities, and body weight in accordance with the particular mode of administration selected and the patient’s needs (e.g., Remington’s Pharmaceutical Science (15th ed., 1980) and Goodman & Gillman, The Pharmacological Basis of Therapeutics (Hardman et al., eds., 1996)).
  • Methods of Extending Telomeres [0291]
  • the instant disclosure provides methods of extending telomeres, comprising the step of administering any of the above-described compounds or compositions to a cell with shortened telomeres, wherein telomeres are extended within the cell.
  • the instant disclosure also provides methods of treatment, comprising the step of administering any of the above-described compounds or compositions to an animal subject in need of, or that may benefit from, telomere extension.
  • the compounds or compositions are administered to a cell, wherein the cell is an isolated cell or is part of a cell culture, an isolated tissue culture, an isolated organ, or the like (i.e., the administration is in vitro).
  • the compounds or compositions are administered without isolating the cell or cells, the tissue, or the organ from the subject (i.e., the administration is in vivo).
  • the compound or composition is delivered to all, or almost all, cells in the subject’s body.
  • the compound or composition is delivered to a specific cell, cell type, tissue, or organ in the subject’s body.
  • Administration of the compounds or compositions of the instant disclosure may result in the transient expression of a telomerase activity in the cell.
  • the increased activity may be measured by various assays, such as, for example, the telomerase repeat amplification protocol (TRAP) assay.
  • TRAP telomerase repeat amplification protocol
  • Commercial versions of the TRAP assay are available, for example the Trapeze® telomerase detection kit (Millipore), which provides a sensitive detection and quantitation of telomerase activity, although other measurement techniques are also possible.
  • TRAP telomerase repeat amplification protocol
  • Millipore Trapeze® telomerase detection kit
  • one of the advantages of the instant techniques is that the expression of telomerase activity is transient in the treated cells.
  • FIG. 1 graphically illustrates some of the advantages of the compounds, compositions, and methods disclosed herein.
  • the speed of telomere extension made possible with these compounds, compositions, and methods enables telomere maintenance by very infrequent delivery of TERT mRNA.
  • telomere activity rapidly extends telomeres in a brief period, before being turned over, thus allowing the protective anti-cancer mechanism of telomere-shortening to function most of the time.
  • normal telomerase activity and telomere shortening is present, and therefore the anti-cancer safety mechanism of telomere shortening to prevent out-of-control proliferation remains intact, while the risk of short telomere-related disease remains low.
  • small molecule treatments for extending telomeres may require chronic delivery, and thus present a chronic cancer risk, with minimal therapeutic benefit.
  • telomere length can be measured using techniques such as terminal restriction fragment (TRF) length analysis, qPCR, MMqPCR, TeSLA, flow FISH, and Q-FISH, as would be understood by one of ordinary skill in the art.
  • TRF terminal restriction fragment
  • the instant methods increase average telomere length in treated cells by at least 0.1 kb, at least 0.2 kb, at least 0.3 kb, at least 0.4 kb, at least 0.5 kb, at least 1 kb, at least 2 kb, at least 3 kb, at least 4 kb, at least 5 kb, or even more.
  • the instant methods reduce the percentage of telomeres with lengths below a certain length, for example 1 kb, 2 kb, 3 kb, 4 kb, 5 kb, or more.
  • telomere shortening mechanism remains intact for most of the time i.e. between treatments.
  • the transient expression of telomerase reverse transcriptase also results in an increased replicative capacity in treated cells. Increased replicative capacity is readily monitored in cells that are approaching replicative senescence by measuring additional population doublings in such cells. Senescent cells do not divide in response to many conditions that cause normal cells to divide, for example passage in culture or treatment with serum.
  • Senescent cells are further often characterized by the expression of pH-dependent ⁇ - galactosidase activity, expression of cell cycle inhibitors p53 and p19, and other altered patterns of gene expression, and an enlarged cell size. It is known in the art that, absent treatment with TERT mRNA, certain types of cells (e.g., human lung fibroblast cells) typically double 50-60 times after birth before senescing; with TERT mRNA treatments, however, these cells achieve an additional 16-28 population doublings. If treated again several weeks later, additional proliferative capacity is conferred again.
  • compositions of the disclosure may treat genetic diseases resulting from mutations in genes not involved directly in telomere maintenance, but resulting in shortened telomeres.
  • Such diseases include, for example, dyskeratosis congenita (DC) and forms of pulmonary fibrosis, lung disease, bone marrow failure, and aplastic anemia.
  • DC dyskeratosis congenita
  • pulmonary fibrosis lung disease
  • bone marrow failure aplastic anemia
  • aplastic anemia a malignant fibrosis .
  • various types of cancer may be prevented or delayed by treatment with compounds of the present disclosure, and indeed chromosome-chromosome fusions caused by critically short telomeres are believed to be a cause of cancer.
  • Therapeutic kits comprising a pharmaceutical composition of a TERT mRNA, or sequences thereof (including complementary sequences), and instructions for use are also contemplated herein.
  • the therapeutic kit comprises devices for administration, including but not limited to syringes, inhalers, nebulizers, and vials or containers.
  • the instant disclosure provides ready-to-use kits for use in extending telomeres in a mammalian cell.
  • the kits comprise any of the above-described compounds or compositions, together with instructions for their use.
  • the kits further comprise packaging materials.
  • the packaging materials are air-tight.
  • the packaging materials may optionally be filled with an inert gas, such as, for example, nitrogen, argon, or the like.
  • the packaging materials comprise a metal foil container, such as, for example, a sealed aluminum pouch or the like. Such packaging materials are well known by those of ordinary skill in the art.
  • the kit may also comprise a delivery vehicle, such as a lipid as described herein.
  • one or more components of the formulation are provided frozen with a cryoprotectant, or lyophilized.
  • the kit may further comprise a desiccant, a culture medium, an RNase inhibitor, or other such components.
  • the kit may further comprise a combination of more than one of these additional components.
  • the composition of the kit is sterile.
  • Embodiment I-1 A composition comprising a (i) a ribonucleic acid (RNA) encoding telomerase reverse transcriptase (TERT) and (ii) a delivery vehicle, wherein the RNA of (i) comprises one or more modified nucleotides and wherein the delivery vehicle of (ii) is operably-linked to the RNA of (i).
  • RNA ribonucleic acid
  • TERT telomerase reverse transcriptase
  • Embodiment I-2 A composition comprising a (i) a ribonucleic acid (RNA) encoding telomerase reverse transcriptase (TERT) and (ii) a delivery vehicle, wherein the RNA of (i) comprises one or more modified nucleotides and wherein the delivery vehicle of (ii) is operably-linked to the RNA of (i).
  • composition of embodiment I-1 wherein the delivery vehicle comprises one or more of a nanoparticle, a liposome, a cationic lipid, an ionizable lipid, an exosome, a lipid nanoparticle, a natural lipoprotein particle and an artificial lipoprotein particle.
  • Embodiment I-3 The composition of embodiment I-1, wherein the delivery vehicle comprises a lipid nanoparticle.
  • Embodiment I-4. The composition of embodiment I-1, wherein the delivery vehicle comprises a ionizable lipid nanoparticle.
  • Embodiment I-5 The composition of any one of embodiments I-1 to I-4, wherein the delivery vehicle comprises a targeting lipid.
  • Embodiment I-6 The composition of any one of embodiments I-1 to I-4, wherein the delivery vehicle comprises a targeting lipid.
  • Embodiment I-5 The composition of embodiment I-5, wherein the targeting lipid specifically or selectively interacts with a liver cell.
  • Embodiment I-7 The composition of embodiment I-6, wherein the targeting lipid comprises cholesterol.
  • Embodiment I-8 The composition of embodiment I-5, wherein the targeting lipid specifically or selectively interacts with a lung cell.
  • Embodiment I-9 The composition of embodiment I-5, wherein the targeting lipid specifically or selectively interacts with a lung cell.
  • composition of embodiment I-8, wherein the targeting lipid comprises 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), N,N-distearyl-N,N- dimethylarnmonium bromide (DABB), or 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (EPC).
  • DOTAP 1,2-dioleoyl-3-trimethylammonium-propane
  • DABB N,N-distearyl-N,N- dimethylarnmonium bromide
  • EPC 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine
  • Embodiment I-11 The composition of embodiment I-10, wherein the compound of Formula I is: . [0324] Embodiment I-12. The composition of embodiment I-10, wherein the compound of Formula I is: [0325] Embodiment I-13. The composition of embodiment I-10, wherein the compound of Formula I is: . [0326] Embodiment I-14. The composition of embodiment I-10, wherein the compound of Formula I is: . [0327] Embodiment I-15. The composition of embodiment I-10, wherein the compound of Formula I is: . [0328] Embodiment I-16. The composition of embodiment I-10, wherein the compound of Formula I is: . [0329] Embodiment I-17.
  • RNA comprises a human sequence of SEQ ID NO: 3 or 4 or a sequence at least 70% identical to the sequence of SEQ ID NO: 3 or 4.
  • Embodiment I-18 The composition of embodiment I-17, wherein the RNA comprises a 5 ⁇ cap.
  • Embodiment I-19 The composition of embodiment I-18, wherein the 5 ⁇ cap comprises an anti-reverse cap analog (ARCA).
  • Embodiment I-20 The composition of embodiment I-19, wherein the ARCA comprises an 3′-O-Me-m7G(5′)ppp(5′)G structure.
  • Embodiment I-21 Embodiment I-21.
  • Embodiment I-22 The composition of any one of embodiments I-1 to I-21, wherein the RNA further comprises at least one untranslated region (UTR). [0335] Embodiment I-23. The composition of embodiment I-22, wherein the at least one UTR is positioned 5′ to the RNA of (i). [0336] Embodiment I-24. The composition of embodiment I-22, wherein the at least one UTR is positioned 3′ to the RNA of (i). [0337] Embodiment I-25.
  • Embodiment I-26 The composition of any one of embodiments I-22 to I-24, wherein the UTR comprises a non-human sequence.
  • Embodiment I-27 The composition of any one of embodiments I-22 to I-26, wherein the UTR comprises a chimeric sequence.
  • Embodiment I-28 The composition of embodiment I-27, wherine the chimeric sequence increases stability, increases a transcription rate or decreases a time until initiation of transcription of the RNA of (i).
  • Embodiment I-29 The composition of any one of embodiments I-22 to I-24, wherein the UTR comprises a human sequence.
  • Embodiment I-26 The composition of any one of embodiments I-22 to I-24, wherein the UTR comprises a non-human sequence.
  • Embodiment I-27 The composition of any one of embodiments I-22 to I-26, wherein the UTR comprises a chimeric sequence
  • Embodiment I-30 The composition of any one of embodiments I-1 to I-29, wherein the one or more modified nucleotides of the RNA of (i) comprise one or more of a modified adenine or analog thereof, a modified cytidine or analog thereof, a modified guanosine or analog thereof, and a modified uridine or analog thereof.
  • Embodiment I-31 Embodiment I-31.
  • Embodiment I-32 The composition of any one of embodiments I-1 to I-31, wherein the one or more modified nucleotides of the RNA of (i) comprise 5-methoxyuridine (5-moU).
  • Embodiment I-33 Embodiment I-33.
  • Embodiment I-34 The composition of any one of embodiments I-1 to I-33, wherein the composition further comprises a ribonucleic acid (RNA) encoding TElomerase RNA Component (TERC).
  • RNA ribonucleic acid
  • TERT TElomerase RNA Component
  • Embodiment I-35 The composition of any one of embodiments I-1 to I-34, wherein the delivery vehicle comprises the RNA encoding TERT.
  • Embodiment I-36 The composition of embodiment I-35, wherein one or more of a surface, a layer or a volume of the delivery vehicle comprises the RNA encoding TERT.
  • Embodiment I-37 The composition of embodiment I-36, wherein the surface comprises an outer surface or an inner surface.
  • Embodiment I-38 The composition of embodiment I-36, wherein the layer comprises a lipid monolayer or lipid bi-layer.
  • Embodiment I-39 The composition of embodiment I-36, wherein the volume comprises an internal volume.
  • Embodiment I-40 The composition of any one of embodiments I-1 to I-39, wherein the delivery vehicle is operably-linked to a ribonucleic acid (RNA) encoding TElomerase RNA Component (TERC).
  • RNA ribonucleic acid
  • TERC ribonucleic acid
  • Embodiment I-41 The composition of embodiment I-40, wherein the delivery vehicle comprises the RNA encoding TERC.
  • Embodiment I-42 The composition of embodiment I-42, wherein the delivery vehicle comprises the RNA encoding TERC.
  • composition of embodiment I-35 wherein one or more of a surface, a layer or a volume of the delivery vehicle comprises the RNA encoding TERC.
  • Embodiment I-43 The composition of embodiment I-42, wherein the surface comprises an outer surface or an inner surface.
  • Embodiment I-44 The composition of embodiment I-42, wherein the layer comprises a lipid monolayer or lipid bi-layer.
  • Embodiment I-45 The composition of embodiment I-42, wherein the volume comprises an internal volume.
  • Embodiment I-46 A method of increasing telomerase activity in a cell, the method comprising contacting the cell and the composition of any one of embodiments I-1 to I-45.
  • Embodiment I-47 A method of extending telomeres in a cell, the method comprising contacting the cell and the composition of any one of embodiments I-1 to I-45.
  • Embodiment I-48 The method of embodiment I-46 or I-47, wherein the cell is in vivo, ex vivo or in vitro.
  • Embodiment I-49 A cell comprising the composition of any one of embodiments I-1 to I-45.
  • Embodiment I-50 A formulation comprising the cell of embodiment I-49.
  • Embodiment I-51 The formulation of embodiment I-50, wherein a plurality of cells comprises the cell of embodiment I-49.
  • Embodiment I-52 The formulation of embodiment I-51, wherein each cell of the plurality is a cell according to embodiment I-49.
  • Embodiment I-53 A method of treating a disease or disorder comprising administering to a subject an effective amount of a composition according to any one of embodiments I-1 to I-45.
  • Embodiment I-54 A method of treating a disease or disorder comprising administering to a subject an effective amount of a cell according to embodiment I-49.
  • Embodiment I-55 A method of treating a disease or disorder comprising administering to a subject an effective amount of a formulation according to any one of embodiments I-50 to I-52.
  • Embodiment I-56 A method of delaying the onset of a disease comprising administering to a subject an effective amount of a composition according to any one of embodiments I-1 to I-45.
  • Embodiment I-57 A method of delaying the onset of a disease comprising administering to a subject an effective amount of a cell according to embodiment I-49.
  • Embodiment I-58 A method of delaying the onset of a disease comprising administering to a subject an effective amount of a formulation according to any one of embodiments I-50 to I-52.
  • Embodiment I-59 A method of delaying the onset of a disease comprising administering to a subject an effective amount of a formulation according to any one of embodiments I-50 to I-52.
  • Embodiment I-60 A composition comprising a lipid nanoparticle particle (LNP) capable of transfecting at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of a population of lung cells.
  • Embodiment I-61 The composition of embodiment I-60, comprising a polynucleotide.
  • Embodiment I-62 The composition of embodiment I-61, wherein the polynucleotide is an RNA.
  • Embodiment I-63 The composition of embodiment I-62, wherein the RNA is an mRNA.
  • Embodiment I-64 The composition of any one of embodiments I-60 to I-63, wherein the LNP is capable of transfecting about 50%-99%, about 60%-99%, about 70%-99%, about 80%-99%, or about 90%-99% of the population of lung cells.
  • Embodiment I-65 The composition of any one of embodiments I-60 to I-63, wherein the LNP is capable of transfecting 50%-95%, about 60%-95%, about 70%-95%, about 80%-95%, or about 90%-95% of the population of lung cells.
  • Embodiment I-66 Embodiment I-66.
  • composition of any one of embodiments I-60 to I-65, wherein the population of lung cells comprises lung endothelial cells.
  • Embodiment I-67 The composition of embodiment I-66, wherein the lung endothelial cells comprise vascular endothelial cells.
  • Embodiment I-68 The composition of embodiment I-66, wherein the lung endothelial cells comprise alveolar endothelial cells.
  • Embodiment I-69 The composition of any one of embodiments I-60 to I-68, wherein the population of lung cells comprises lung epithelial cells.
  • Embodiment I-70 Embodiment I-70.
  • Embodiment I-69 wherein the lung epithelial cells comprise lung alveolar epithelial cells.
  • Embodiment I-71 The composition of embodiment I-70, wherein the lung alveolar epithelial cells comprise alveolar type 1 (AT1) cells.
  • Embodiment I-72 The composition of embodiment I-70, wherein the lung alveolar epithelial cells comprise alveolar type 2 (AT2) cells.
  • Embodiment I-73 The composition of any one of embodiments I-60 to I-72, wherein the lung cells comprise any one or more of macrophages, mast cells, club cells, brush cells, neuroepithelial cells, and goblet cells.
  • Embodiment I-74 The composition of embodiment I-74.
  • Embodiment I-75 The composition of any one of embodiments I-60 to I-74, wherein the population of lung cells comprise bronchial cells.
  • Embodiment I-76 The composition of any one of embodiments I-60 to I-75, wherein the population of lung cells comprises bronchioalveolar stem cells.
  • Embodiment I-77 The composition of any one of embodiments I-60 to I-76, wherein the population of lung cells comprises lung immune cells.
  • Embodiment I-78 The composition of any one of embodiments I-60 to I-73, wherein the lung cells comprise one or more of fibroblasts, myofibroblasts, lipofibroblasts, and fibromyocytes.
  • composition of any one of embodiments I-60 to I-77, wherein the population of lung cells comprises lung fibroblasts.
  • the composition of any one of embodiments I-60 to I-78, wherein the population of lung cells comprises one or more of lung precancerous and cancer cells.
  • composition of any one of embodiments I-60 to I-79 wherein the population of lung cells comprise lung alveolar endothelial cells and lung alveolar epithelial cells, and at least 60%, at least 70%, at least 80%, or at least 90% of the lung endothelial cells are transfected, and at least 60%, at least 70%, at least 80%, or at least 90% of the lung epithelial cells are transfected.
  • Embodiment I-81 The composition of any one of any one of embodiments I-60 to I-80, wherein the lung cells are transfected when administered to a subject by intravenous injection.
  • Embodiment I-82 Embodiment I-82.
  • composition of any one of embodiments I-60 to I-80, the lung cells are transfected when administered to a subject by one or more of aerosol injection, aerosolization, inhalation, nebulization or instillation.
  • Embodiment I-83 The composition of any one of embodiments I-60 to I-82, wherein the composition comprises an ionizable lipid.
  • Embodiment I-84 The composition of embodiment I-83, wherein the ionizable lipid is about 40-60% of the molar percentage of the LNP.
  • Embodiment I-85 Embodiment I-85.
  • composition of any one of embodiments I-60 to I-84 wherein the composition comprises a compound of Formula I: , [0398] wherein R 1a and R 1b each independently represents an alkylene group having 1 to 6 carbon atoms, wherein X a and X b are each independently an acyclic alkyl tertiary amino group having 1 to 6 carbon atoms and 1 tertiary amino group, or 2 to 5 carbon atoms, and A cyclic alkylene tertiary amino group having 1 to 2 tertiary amino groups, [0399] wherein R 2a and R 2b each independently represent an alkylene group having 8 or less carbon atoms or an oxydialkylene group, [0400] wherein Y a and Y b each independently represent an ester bond, an amide bond, a carbamate bond, an ether bond or a urea bond; [0401] wherein Z a and Z b are each independently a divalent group derived from an aromatic compound having
  • Embodiment I-86 The composition of embodiment I-84, wherein the compound of Formula I is: . [0404] Embodiment I-87. The composition of embodiment I-84, wherein the compound of Formula I is: . [0405] Embodiment I-88. The composition of embodiment I-84, wherein the compound of Formula I is: . [0406] Embodiment I-89. The composition of embodiment I-84, wherein the compound of Formula I is: . [0407] Embodiment I-90. The composition of embodiment I-84, wherein the compound of Formula I is: . [0408] Embodiment I-91.
  • Embodiment I-84 wherein the compound of Formula I is: [0409] Embodiment I-92.
  • Embodiment I-93 The composition of any one of embodiments I-60 to I-92, wherein the LNP comprises a mixture of two or more ionizable lipids.
  • Embodiment I-94 The composition of any one of embodiments I-82 to I-92, wherein the cationic lipid is an ionizable lipid and a targeting lipid.
  • Embodiment I-95 Embodiment I-95.
  • Embodiment I-100 The composition of any one of embodiments I-98 to I-99, wherein the PEGylated lipid is linear.
  • Embodiment I-101 The composition of any one of embodiments I-98 to I-99, wherein the PEGylated lipid is branched.
  • Embodiment I-102 The composition of any one of embodiments I-98 to I-101, wherein the PEGylated lipid comprises a carbon chain having between 8 and 24 carbon atoms.
  • Embodiment I-103 Embodiment I-103.
  • Embodiment I-104 The composition of any one of embodiments I-98 to I-101, wherein the insulator lipid is at least 0.25-5% of the molar percentage of the LNP.
  • Embodiment I-105 The composition of any one of embodiments I-1 to I-104, wherein the LNP comprises a cationic lipid.
  • Embodiment I-106 Embodiment I-106.
  • composition of embodiment I-105 wherein the cationic lipid is any one or more of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and a DOTAP analog.
  • DOTAP 1,2-dioleoyl-3-trimethylammonium-propane
  • Embodiment I-107 Embodiment I-107.
  • composition of embodiment I-105 wherein the cationic lipid is any one or more of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 5-carboxyspermylglycinedioctadecylamide (DOGS), 2,3-dioleyloxy-N- [2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanaminium (DOSPA), 1,2-Dioleoyl-3- Dimethylammonium-Propane (DODAP), 1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP), 1,2-distearyloxy-N,N-dimethyl-3-aminopropane (DSDMA), 1,2-dioleyloxy-N,N- dimethyl-3-aminopropane (DODMA), 1,2-dilinoleyloxy-N,N-di
  • Embodiment I-108 The composition of any one of embodiments I-1 to I-107, wherein the LNP comprises a structural lipid.
  • the structural lipid is any one or more of 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), glycerol-monooleate (GMO), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloylo
  • Embodiment I-110 The composition of any one of embodiments I-1 to I-109, wherein the LNP comprises at least a first component, a second component, and a third component, wherein: [0428] the first component is an ionizable lipid; [0429] the second component is a cationic lipid; and [0430] the third component is a structural lipid. [0431] Embodiment I-111. The composition of embodiment I-110, further comprising a sterol. [0432] Embodiment I-112.
  • composition of any one of embodiments I-110 to I-111 comprising an insulator lipid selected from: 14:0 PEG2000 PE and a DMG-PEGylated lipid., and a lipid conjugated to a blood protein or a peptide sequence of a blood protein, wherein the blood protein is albumin or a globulin.
  • Embodiment I-113 The composition of any one of embodiments I-1 to I-112, wherein the LNP comprises SS-OP or an SS-OP analog, DOPC, a cholesterol, DMG-PEG2000, and DOTAP.
  • Embodiment I-114 Embodiment I-114.
  • Embodiment I-113 wherein the LNP comprises 45-55% cationic lipid and SS-OP or an analog thereof at between 20-40%.
  • Embodiment I-115 The composition of embodiment I-114, wherein the LNP comprise 45-55% DOTAP.
  • Embodiment I-116 The LNP of embodiment I-113, wherein the LNP comprises SS-OP, DOPC, a cholesterol, DMG-PEG2000, and DOTAP.
  • Embodiment I-117 The composition of embodiment I-114, wherein the LNP comprises 25-29% of SS-OP; 1-3% DOPC; 15-35% cholesterol; 0.8-1.6% DMG-PEG2000; and 45-55% DOTAP.
  • Embodiment I-118 The composition of embodiment I-114, wherein the LNP comprises 27% of SS-OP; 2.5% DOPC; 20% cholesterol; 1.2% DMG-PEG2000; and 50% DOTAP.
  • Embodiment I-119 The composition of any one of embodiments I-60 to I-118, wherein the LNP comprises cKK-E12 or a cKK-E12 analog, DOPE, a cholesterol, PEG2000 PE, and DOTAP.
  • Embodiment I-120 Embodiment I-120.
  • Embodiment I-121 A method of treating a lung disease or disorder in a subject in need thereof, comprising administering the composition of any one of embodiments I-1 to I-45 or embodiments I-60 to I-119 to the subject.
  • Embodiment I-122 The method of any one of embodiments I-120 to I-121, the method comprising administering the composition by intravenous injection.
  • Embodiment I-123 The method of any one of embodiments I-120 to I-121, the method comprising administering the composition by intravenous injection.
  • Embodiment I-124 The method of any one of embodiments I-120 to I-121, the method comprising administering the LNP by one or more of aerosol injection, aerosolization, inhalation, nebulization or instillation.
  • Embodiment I-124 The method of any one of embodiments I-120 to I-123, wherein the cargo comprises a polynucleotide.
  • Embodiment I-125 The method of embodiment I-124, wherein the polynucleotide is an RNA.
  • Embodiment I-126 The method of embodiment I-125, wherein the RNA is an mRNA.
  • Embodiment I-127 Embodiment I-127.
  • Embodiment I-128 The method of any one of embodiments I-120 to I-127, wherein at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of a population of lung cells of the subject are transfected. [0449] Embodiment I-129.
  • Embodiment I-130 The method of any one of embodiments I-120 to I-129, wherein about 50%-95%, about 60%-95%, about 70%-95%, about 80%-95%, or about 90%-95% of a population of lung cells of the subject are transfected. [0451] Embodiment I-131.
  • Embodiment I-132 The method of any one of embodiments I-120 to I-131, wherein the LNP is administered to the subject as a single dose.
  • Embodiment I-133 The method of any one of embodiments I-120 to I-131, wherein the LNP is administered to the subject as a single dose.
  • Embodiment I-134 The method of any one of embodiments I-120 to I-133, wherein a dose of the LNP is administered to the subject is at least 0.01, 0.1, 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, or 80 mg/kg by weight of the subject. [0455] Embodiment I-135.
  • Embodiment I-136 The method of any one of embodiments I-120 to I-135, wherein the subject is human.
  • Embodiments II [0457] Embodiment II-1.
  • a method of delivering a polynucleotide to the lung of a subject comprising administering, by intravenous injection, a polynucleotide encapsulated in a lipid nanoparticle (LNP) comprising: [0458] (i) a cationic lipid in a molar percentage of between about 20% and about 50%, [0459] (ii) a SS-OP or an SS-OP analog at a molar percentage of between about 20% and about 60%. [0460] Embodiment II-2.
  • LNP lipid nanoparticle
  • Embodiment II-3 The method of embodiment II-1 or II-2, wherein the cationic lipid is is any one or more of 2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP), Dimethyldioctadecylammonium bromide (DDAB), Imidazole Cholesterol Ester (ICE), 25- Hydroxycholesterol (25 OH Chol), 20 ⁇ -hydroxycholesterol 5-cholestene-3 ⁇ , 20 ⁇ -diol (20 ⁇ Chol), N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 5- carboxyspermylglycinedioctadecylamide (DOGS), 2,3-dioleyloxy-N
  • DOTAP 2-Dioleoyl-3-Trimethylammonium-Propane
  • DDAB Dimethyldioctadecylammonium bromide
  • ICE
  • Embodiment II-4 The method of embodiment II-4, wherein the cationic lipid is DOTAP.
  • Embodiment II-5 The method of any one of embodiments II-1 to II-4, wherein the LNP comprises the cationic lipid at a molar percentage of between about 25% and about 35%.
  • Embodiment II-6 The method of any one of embodiments II-1 to II-4, wherein the LNP comprises the cationic lipid at a molar percentage of about 30%.
  • Embodiment II-7 The method of any one of embodiments II-1 to II-6, wherein the LNP comprises a structural lipid.
  • Embodiment II-8 The method of any one of embodiments II-8.
  • the structural lipid is any one or more of 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), glycerol-monooleate (GMO), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N- maleimidomethyl)-cyclohexane-1-carboxy
  • Embodiment II-9 The method of embodiment II-7, wherein the structural lipid is DOPC.
  • Embodiment II-10 The method of embodiment II-9, wherein the LNP comprises between about 1% and about 5% DOPC.
  • Embodiment II-11 The method of any one of embodiments II-1 to II-6, wherein the LNP is substantially free of structural lipids and/or comprises at most 1% structural lipids.
  • Embodiment II-12 The method of any one of embodiments II-1 to II-11, wherein the LNP comprises between about 20% and about 40% cholesterol.
  • Embodiment II-13 The method of any one of embodiments II-1 to II-11, wherein the LNP is substantially free of cholesterol.
  • Embodiment II-14 The method of any one of embodiments II-1 to II-13, wherein the LNP comprises an insulator lipid.
  • Embodiment II-15 The method of any one of embodiments II-1 to II-13, wherein the LNP is substantially free of insulator lipids.
  • Embodiment II-16 The method of any one of embodiments II-1 to II-15, wherein the LNP preferentially delivers to and/or transfects the lung compared to liver.
  • Embodiment II-17 The method of any one of embodiments II-1 to II-16, wherein the polynucleotide is a synthetic ribonucleic acid (RNA).
  • Embodiment II-18 The method of any one of embodiments II-18.
  • Embodiment II-19 A method of treating a lung fibrosis in a subject in need thereof, comprising administering an effective amount of a composition comprising a delivery vehicle comprising a synthetic ribonucleic acid (RNA) encoding telomerase reverse transcriptase (TERT).
  • RNA synthetic ribonucleic acid
  • TERT telomerase reverse transcriptase
  • Embodiment II-20 wherein the LNP comprises a cationic lipid at a molar percentage of between about 20% and about 50%, a SS-OP or an SS- OP analog at a molar percentage of between about 20% and 60%, and optionally one or more of a structural lipid, an insulator lipid, and a cholesterol.
  • Embodiment II-22 The method of any one of embodiments II-19 to II-21, wherein the TERT synthetic mRNA comprises at least one modified nucleoside from the list in Table 2.
  • Embodiment II-23 The method of embodiment II-22, wherein the modified nucleoside is pseudouridine or a pseudouridine analog.
  • Embodiment II-24 Embodiment II-24.
  • Embodiment II-25 The method of any one of embodiments II-19 to II-24, wherein the TERT synthetic mRNA comprises an untranslated region (UTR).
  • Embodiment II-26 The method of any one of embodiments II-19 to II-24, wherein the TERT synthetic mRNA comprises an untranslated region (UTR).
  • the TERT synthetic mRNA comprises a 5 ⁇ cap structure, wherein the 5 ⁇ cap structure is m7(3 ⁇ OMeG)(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OMeA)pG, IRES, Cap0, Capl, ARCA, inosine, Nl-methyl- guanosine, 2 ⁇ fluoro-guanosine, 7-deaza-guanosine, CleanCapTM, 8-oxo-guanosine, 2-amino- guanosine, LNA-guanosine, 2-azido-guanosine, Cap2, Cap4, CAP-003, or CAP-225.
  • Embodiment II-27 Embodiment II-27.
  • the TERT synthetic mRNA comprises a chain terminating nucleotide, wherein the nucleotide is 3 ⁇ -deoxyadenosine (cordycepin), 3 ⁇ -deoxyuridine, 3 ⁇ -deoxycytosine, 3 ⁇ -deoxyguanosine, 3 ⁇ - deoxythymine, 2 ⁇ ,3 ⁇ -dideoxynucleosides, 2 ⁇ ,3 ⁇ -dideoxyadenosine, 2 ⁇ ,3 ⁇ -dideoxyuridine, 2 ⁇ ,3 ⁇ - dideoxycytosine, 2 ⁇ ,3 ⁇ - dideoxyguanosine, 2 ⁇ ,3 ⁇ -dideoxythymine, a 2 ⁇ -deoxynucleoside, or -O- methylnucleoside.
  • the nucleotide is 3 ⁇ -deoxyadenosine (cordycepin), 3 ⁇ -deoxyuridine, 3 ⁇ -deoxycytosine, 3 ⁇ -deoxyguanosine, 3 ⁇ - deoxythymine, 2 ⁇ ,3
  • Embodiment II-29 The method of any one of embodiments II-19 to II-28, wherein the TERT synthetic mRNA is codon optimized.
  • Embodiment II-30 The method of any one of embodiments II-19 to II-28, wherein the lung fibrosis is associated with a lung disease.
  • Embodiment II-31 The method of embodiment II-30, wherein the lung disease is pulmonary fibrosis, familial pulmonary fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis associated with dyskeratosis congenita, an interstitial lung disease, pneumonia, interstitial pneumonia, emphysema, or lung cancer.
  • Embodiment II-32 The method of any one of embodiments II-19 to II-31, wherein the lung fibrosis is associated with a TERT mutation.
  • Embodiment II-33 The method of any one of embodiments II-19 to II-32, wherein the subject is human.
  • Embodiment II-34 The method of any one of embodiments II-19 to II-33, wherein the composition is administered to the subject via intravenous injection.
  • Embodiment II-35 The method of any one of embodiments II-19 to II-33, wherein the composition is administered to the subject via inhalation.
  • Embodiment II-36 The method of any one of embodiments II-19 to II-31, wherein the lung fibrosis is associated with a TERT mutation.
  • Embodiment II-33 The method of any one of embodiments II-19 to II-32, wherein the subject is human.
  • Embodiment II-34 The method of any one of embodiments II-19 to II-33, wherein the composition is administered to the subject via intra
  • a composition comprising a polynucleotide encapsulated in a lipid nanoparticle (LNP) comprising: [0495] (i) a cationic lipid in a molar percentage of between about 20% and about 50%, [0496] (ii) a SS-OP or an SS-OP analog at a molar percentage of between about 20% and about 60%. [0497] Embodiment II-37.
  • the composition of embodiment II-36, wherein the SS-OP analog is any one or more of SS-M, SS-E, SS-EC, SS-LC, and SS-OC.
  • Embodiment II-38 Embodiment II-38.
  • composition of embodiment II-36, wherein the cationic lipid is is any one or more of 2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP), Dimethyldioctadecylammonium bromide (DDAB), Imidazole Cholesterol Ester (ICE), 25- Hydroxycholesterol (25 OH Chol), 20 ⁇ -hydroxycholesterol 5-cholestene-3 ⁇ , 20 ⁇ -diol (20 ⁇ Chol), N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 5- carboxyspermylglycinedioctadecylamide (DOGS), 2,3-dioleyloxy-N-[2(spermine- carboxamido)ethyl]-N,N-dimethyl-1-propanaminium (DOSPA), 1,2-Dioleoyl-3- Dimethylammonium-Propane (DOD
  • Embodiment II-39 The composition of embodiment II-38, wherein the cationic lipid is DOTAP.
  • Embodiment II-40 The composition of any one of embodiments II-36 to II-39, wherein the LNP comprises the cationic lipid at a molar percentage of between about 25% and about 35%.
  • Embodiment II-41 The composition of any one of embodiments II-36 to II-39, wherein the LNP comprises the cationic lipid at a molar percentage of about 30%.
  • Embodiment II-42 The composition of any one of embodiments II-36 to II-41, wherein the LNP comprises a structural lipid.
  • Embodiment II-43 The composition of any one of embodiments II-36 to II-41, wherein the LNP comprises a structural lipid.
  • composition of embodiment II-42 wherein the structural lipid is any one or more of 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), glycerol-monooleate (GMO), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N- maleimidomethyl)-cyclohexane-1-carbox
  • Embodiment II-44 The composition of embodiment II-43, wherein the structural lipid is DOPC.
  • Embodiment II-45 The composition of embodiment II-44, wherein the LNP comprises between about 1% and about 5% DOPC.
  • Embodiment II-46 The compositon of any one of embodiments II-36 to II-45, wherein the LNP is substantially free of structural lipids and/or comprises at most 1% structural lipids.
  • Embodiment II-47 The composition of any one of embodiments II-36 to II-46, wherein the LNP comprises between about 20% and about 40% cholesterol.
  • Embodiment II-48 Embodiment II-48.
  • composition of any one of embodiments II-36 to II-46, wherein the LNP is substantially free of cholesterol.
  • Embodiment II-49 The composition of any one of embodiments II-36 to II-48, wherein the LNP comprises an insulator lipid.
  • Embodiment II-50 The composition of any one of embodiments II-36 to II-48, wherein the LNP is substantially free of insulator lipids.
  • Embodiment II-51 The composition of any one of embodiments II-36 to II-50, wherein the LNP preferentially delivers to and/or transfects the lung compared to liver.
  • Embodiment II-52 The composition of any one of embodiments II-36 to II-52.
  • RNA RNA
  • Embodiment II-53 The composition of embodiment II-52, wherein the synthetic ribonucleic acid (RNA) encodes telomerase reverse transcriptase (TERT).
  • TERT telomerase reverse transcriptase
  • Embodiment II-54 The composition of embodiment II-53, wherein the TERT synthetic RNA comprises at least one modified nucleoside from the list in Table 2.
  • Embodiment II-55 The composition of embodiment II-54, wherein the modified nucleoside is pseudouridine or a pseudouridine analog.
  • Embodiment II-56 Embodiment II-56.
  • composition of embodiment II-54 wherein the pseudouridine analog is N-1-methylpseudouridine.
  • Embodiment II-57 The composition of embodiments II-53 to II-56, wherein the TERT synthetic RNA comprises an untranslated region (UTR).
  • UTR untranslated region
  • Embodiment II-59 Embodiment II-59.
  • composition of any one of embodiments II-53 to II-58, wherein the TERT synthetic RNA comprises a poly-adenosine (poly-A) nucleotide sequence 3 ⁇ to the encoding region [0520] Embodiment II-60.
  • the nucleotide is 3 ⁇ -deoxyadenosine (cordycepin), 3 ⁇ -deoxyuridine, 3 ⁇ -deoxycytosine, 3 ⁇ - deoxyguanos
  • Embodiment II-61 The composition of any one of embodiments II-53 to II-60, wherein the TERT synthetic RNA is codon optimized.
  • Embodiment II-62 Use of the composition of any one of embodiments II-36 to II- 61, for the treatment of lung fibrosis in a subject in need thereof.
  • Embodiment II-63 Use of the composition of any one of embodiments II-36 to II- 61, for the treatment of lung fibrosis in a subject in need thereof.
  • composition according to embodiment II-62 wherein the lung fibrosis is associated with a lung disease, and wherein the lung disease is pulmonary fibrosis, familial pulmonary fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis associated with dyskeratosis congenita, an interstitial lung disease, pneumonia, interstitial pneumonia, emphysema, or lung cancer.
  • the lung disease is pulmonary fibrosis, familial pulmonary fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis associated with dyskeratosis congenita, an interstitial lung disease, pneumonia, interstitial pneumonia, emphysema, or lung cancer.
  • Embodiment II-64 Use of the composition according to embodiment II-62 or II- 63, wherein the lung fibrosis is associated with a TERT mutation in the subject.
  • Embodiment II-65 Use of the composition according to embodiment II-62 or II- 63,
  • Embodiment II-66 A pharmaceutical composition comprising: [0527] (i) a delivery vehicle comprising a ribonucleic acid (RNA) encoding telomerase reverse transcriptase (TERT); and [0528] (ii) and a pharmaceuticaly acceptable solvent or excipient; [0529] wherein the delivery vehicle is capable of preferentially delivering to and/or transfecting lung cells. [0530] Embodiment II-67. The pharmaceutical composition of embodiment II-66, wherein the delivery vehicle is an LNP. [0531] Embodiment II-68.
  • RNA ribonucleic acid
  • TERT telomerase reverse transcriptase
  • the pharmaceutical composition of embodiment II-67, wherein the LNP comprises: [0532] (i) a cationic lipid in a molar percentage of between about 20% and about 50%; and [0533] (ii) a SS-OP or an SS-OP analog at a molar percentage of between about 20% and about 60%.
  • the pharmaceutical composition of embodiment II-68, wherein the SS-OP analog is any one or more of SS-M, SS-E, SS-EC, SS-LC, and SS-OC.
  • Embodiment II-70 Embodiment II-70.
  • Embodiment II-71 The pharmaceutical composition of embodiment II-70, wherein the cationic lipid is DOTAP.
  • Embodiment II-72. The pharmaceutical composition of any one of embodiments II-68 to II-71, wherein the LNP comprises the cationic lipid at a molar percentage of between about 25% and about 35%.
  • Embodiment II-73. The pharmaceutical composition of any one of embodiments II-68 to II-71, wherein the LNP comprises the cationic lipid at a molar percentage of about 30%.
  • Embodiment II-74 The pharmaceutical composition of any one of embodiments II-68 to II-73, wherein the LNP comprises a structural lipid.
  • Embodiment II-75 The pharmaceutical composition of embodiment II-74, wherein the structural lipid is any one or more of 1,2-di-(9Z-octadecenoyl)-sn-glycero-3- phosphoethanolamine (DOPE), glycerol-monooleate (GMO), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N- maleimid
  • DOPE
  • Embodiment II-76 The pharmaceutical composition of embodiment II-75, wherein the structural lipid is DOPC.
  • Embodiment II-77 The pharmaceutical composition of embodiment II-76, wherein the LNP comprises between about 1% and about 5% DOPC.
  • Embodiment II-78 The pharmaceutical compositon of any one of embodiments II- 68 to II-77, wherein the LNP is substantially free of structural lipids and/or comprises at most 1% structural lipids.
  • Embodiment II-79 The pharmaceutical composition of any one of embodiments II-68 to II-78, wherein the LNP comprises between about 20% and about 40% cholesterol.
  • Embodiment II-80 Embodiment II-80.
  • Embodiment II-81 The pharmaceutical composition of any one of embodiments II-68 to II-80, wherein the LNP comprises an insulator lipid.
  • Embodiment II-82 The pharmaceutical composition of any one of embodiments II-68 to II-80, wherein the LNP is substantially free of insulator lipids.
  • Embodiment II-83 The pharmaceutical composition of any one of embodiments II-68 to II-82, wherein the LNP preferentially delivers to and/or transfects the lung compared to liver.
  • Embodiment II-84 The pharmaceutical composition of any one of embodiments II-68 to II-82, wherein the LNP preferentially delivers to and/or transfects the lung compared to liver.
  • the pharmaceutical composition of any one of embodiments II-66 to II-83, wherein the TERT synthetic RNA comprises at least one modified nucleoside from the list in Table 2.
  • Embodiment II-85 The pharmaceutical composition of embodiment II-84, wherein the modified nucleoside is pseudouridine or a pseudouridine analog.
  • Embodiment II-86 The pharmaceutical composition of embodiment II-85, wherein the pseudouridine analog is N-1-methylpseudouridine.
  • Embodiment II-87 The pharmaceutical composition of embodiments II-66 to II- 86, wherein the TERT synthetic RNA comprises an untranslated region (UTR).
  • Embodiment II-88 The pharmaceutical composition of any one of embodiments II-66 to II-83, wherein the TERT synthetic RNA comprises at least one modified nucleoside from the list in Table 2.
  • Embodiment II-85 The pharmaceutical composition of embodiment II-84, wherein the modified nucleoside is pseudouridine or a pseudouridine analog.
  • Embodiment II-86
  • the TERT synthetic RNA comprises a 5 ⁇ cap structure, wherein the 5 ⁇ cap structure is m7(3 ⁇ OMeG)(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OMeA)pG, IRES, Cap0, Capl, ARCA, inosine, Nl-methyl-guanosine, 2 ⁇ fluoro-guanosine, 7-deaza-guanosine, CleanCapTM, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azido-guanosine, Cap2, Cap4, CAP- 003, or CAP-225.
  • the 5 ⁇ cap structure is m7(3 ⁇ OMeG)(5 ⁇ )ppp(5 ⁇ )(2 ⁇ OMeA)pG, IRES, Cap0, Capl, ARCA, inosine, Nl-methyl-guanosine, 2 ⁇ fluoro-guanosine, 7-deaza-guanosine, CleanCapTM, 8-ox
  • Embodiment II-89 The pharmaceutical composition of any one of embodiments II-66 to II-88, wherein the TERT synthetic RNA comprises a poly-adenosine (poly-A) nucleotide sequence 3 ⁇ to the encoding region.
  • Embodiment II-90 The pharmaceutical composition of any one of embodiments II-66 to II-88, wherein the TERT synthetic RNA comprises a poly-adenosine (poly-A) nucleotide sequence 3 ⁇ to the encoding region.
  • the TERT synthetic RNA comprises a chain terminating nucleotide, wherein the nucleotide is 3 ⁇ -deoxyadenosine (cordycepin), 3 ⁇ -deoxyuridine, 3 ⁇ -deoxycytosine, 3 ⁇ -deoxyguanosine, 3 ⁇ -deoxythymine, 2 ⁇ ,3 ⁇ -dideoxynucleosides, 2 ⁇ ,3 ⁇ -dideoxyadenosine, 2 ⁇ ,3 ⁇ - dideoxyuridine, 2 ⁇ ,3 ⁇ -dideoxycytosine, 2 ⁇ ,3 ⁇ - dideoxyguanosine, 2 ⁇ ,3 ⁇ -dideoxythymine, a 2 ⁇ - deoxynucleoside, or -O- methylnucleoside.
  • the nucleotide is 3 ⁇ -deoxyadenosine (cordycepin), 3 ⁇ -deoxyuridine, 3 ⁇ -deoxycytosine, 3 ⁇ -deoxyguanosine, 3 ⁇ -deoxythymine, 2 ⁇ ,3 ⁇
  • Embodiment II-91 The pharmaceutical composition of any one of embodiments II-66 to II-90, wherein the TERT synthetic RNA is codon optimized.
  • Embodiment II-92 Use of the pharmaceutical composition of any one of embodiments II-66 to II-91, for the treatment of lung fibrosis in a subject in need thereof.
  • Embodiment II-93 Use of the pharmaceutical composition of any one of embodiments II-66 to II-91, for the treatment of lung fibrosis in a subject in need thereof.
  • Embodiment II-92 Use of the pharmaceutical composition according to embodiment II-92, wherein the lung fibrosis is associated with a lung disease, and wherein the lung disease is pulmonary fibrosis, familial pulmonary fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis associated with dyskeratosis congenita, an interstitial lung disease, pneumonia, interstitial pneumonia, emphysema, or lung cancer.
  • Embodiment II-94 Use of the pharmaceutical composition according to embodiment II-92 or II-93, wherein the lung fibrosis is associated with a TERT mutation in the subject.
  • Embodiment II-95 Use of the pharmaceutical composition according to embodiment II-92 or II-93, wherein the lung fibrosis is associated with a TERT mutation in the subject.
  • compositions and methods of the disclosure may be used for delivery of cargo, such as a polynucleotide, by a delivery vehicle to lung cells.
  • the delivery vehicle is a lipid nanoparticle (LNP) as disclosed herein.
  • the LNPs disclosed herein are used for delivery of an mRNA to a population of lung cells.
  • Tables 6A-6B below show exemplary formulations for an LNP that can be used as a delivery vehicle
  • Table 6C below shows example ranges of molar percentages for an LNP with classes of lipids that can be used as a delivery vehicle.
  • FIG.2 depicts a representative dynamic light scattering (DLS) plot of the mRNA- LNPs made using the exemplary lipid components shown in Table 6A.
  • FIG.3 depicts bioluminescent imaging of whole organs in mice that were injected with mRNA-LNPs.
  • mRNA-LNPs were prepared by formulated using microfluidic mixing, and were next processed by concentration and buffer exchange prior to injection.
  • the organs were harvested and imaged 26 hours after the mice were dosed intravenously with Luciferase mRNA-LNPs at 0.6mg/kg of total mRNA to body weight.
  • the bioluminescent imaging demonstrates that the LNP delivery vehicles were capable of delivering mRNA cargo to the lung.
  • FIGS. 4A-4B depict immunohistochemistry staining for tdTomato in lung cells from a mouse treated with an mRNA reporter, and an untreated control mouse, respectively.
  • tdTomato fl/fl mice were dosed intravenously with Cre mRNA LNPs at 0.6mg/kg or saline. Lungs were harvested 4 days later.
  • FIGS.4A- 4B the scale bar is 50 ⁇ M.
  • FIGS. 5A-5B depict measurements of telomerase activity in mouse lung after delivery of TERT mRNA-LNP, and in mouse lung of an untreated control, respectively.
  • TERT knockout (KO) mice were dosed intravenously with TERT mRNA LNPs at 2.0 mg/kg and lungs were harvested 19 hours later. As a control, lungs were also harvested from an untreated TERT KO mouse.
  • the telomere repeat amplification protocol (TRAP) was run on lung lysates.
  • the banding pattern observed in the lung lysate of the TERT mRNA LNP treated mouse demonstrates that telomerase activity was present.
  • the TRAP assay was performed as follows. Protein lysate from cells or tissues was incubated with an artificial telomere (DNA oligonucleotide). If active telomerase is present, it extends the artificial telomere 6 bp at a time, producing a ladder pattern. This extension reaction is then amplified by PCR and run on a gel (Agilent bioanalyzer, using a microfluidic agarose gel). The presence of a ladder in 6 bp increments indicates telomerase activity.
  • FIG.6A is a bar graph depicting the transfection efficiency of an exemplary lung delivery vehicle formulation, as a function of Cre dose, number of doses, and genotype in mice. Cre mRNA complexed with the LNP lung vehicle of the Table 6A was delivered at the indicated doses via tail vein injection to mice carring a tdTomato reporter gene that requires Cre to turn on. Lungs were harvested for histological analysis by immunostaining of the reporter gene. FIG. 6A demonstrates that the Cre mRNA LNPs formulation transfected the cells of the lung and turned on the reporter gene in a dose-dependent manner.
  • FIGS.6B-6F depict representative images of lung sections harvested from the mice as described above, with the reporter protein shown as a darkened stain.
  • Lung cells were harvested after treatment with saline control (FIG.6B), 0.1 mg/kg (FIG.6C), 0.3 mg/kg (FIG. 6D), 0.6 mg/kg (FIG.6E), or 2.0 mg/kg (FIG.6F) by body weight dose of the mRNA.
  • FIGS.7A-7C depict computed tomography (CT) X-ray scans of mouse lungs tested for lung fibrosis.
  • CT computed tomography
  • FIG.7A depicts a control with no bleomycin treatment
  • FIGS.7B-7C depict use of 1 U/kg bleomycin for inducing lung fibrosis.
  • FIGS.7B-7C were treated with saline and TERT mRNA LNPs, respectively. Healthy lung tissue appears darker, and fibrotic lung tissue appears lighter. Less fibrosis is shown in the TERT mRNA LNP-treated mouse than in the saline-treated control.
  • FIG. 8 depicts a graph showing the mortality of mice dosed with various formulations of lung-targeted LNPs.
  • FIGS. 9A-9D depict various lung samples from mice treated with bleomycin for inducing lung fibrosis, and treated with CRE mRNA or saline to show delivery of the mRNA to alveolar cells.
  • mice were given 1 U/kg bleomycin via oral aspiration (OA) to induce fibrosis.
  • OA oral aspiration
  • mice were dosed with saline or 2 mg/kg Cre mRNA, translation of which allows for tdTomato expression.
  • mice were sacrificed and the lungs were fixed by inflation with PFA. Lung sections were stained with anti-tdTomato antibody and trichrome.
  • Example 9 Lung delivery of mRNA by SS-OP DOTAP IV and OA routes
  • LNP lipid nanoparticles
  • Luc firefly luciferase
  • Tables 2A and 2B The lipid to mRNA ratios (wt/wt) used in these experiments were 75:1 and 40:1.
  • C57Bl/6 mice were dosed with the LNP-mRNAs at 0.5 mg/kg via intravenous injection (IV) or 0.2 mg/kg via oropharyngeal aspiration (OA). Lungs were imaged ex vivo 24 hours later.
  • FIG.10 shows the mean radiance of luciferase in the lung (photons/s/cm2/sr).
  • Intravenous administration of the SS-OP DOTAP formulation provided significantly higher lung transfection (FIGS. 10 and 11) than through oral administration.
  • SS-OP DOTAP LNPs with a lipid: RNA ratio of either 75:1 or 40:1 lipid: RNA exhibited similar transfection efficiencies when dosed intravenously.
  • Example 10 Positively charged lipids targeted mRNA to the lung [0575]
  • Tomato fl/fl mice were dosed with various LNP formulations encapsulating Cre mRNA, delivered intravenously in a range of 0.1 – 0.5 mg/kg, as shown in FIG.12.
  • the lipid to mRNA ratio for the SS-OP DOTAP formulation, the SS-OP 20 ⁇ Chol formulation, the SS-OP DDAB formulation, and the 25 OH Chol was 80 ⁇ mol lipid: 1 mg mRNA.
  • the lipid to mRNA ratio for SS-OP ICE was 50:1.
  • the lipid to mRNA ratio for the SS-OP DOTAP ICE formulation was 70: 1. Lungs were harvested 3 days later and processed via formalin fixation and paraffin embedding. Positive cells were labeled with anti-tdTomato antibody. FIG. 12 shows the percent positive Tomato cells in the lung parenchyma. [0576] The results of the transfection are shown in FIG.12 Notably, other cationic lipids with a net positive charge at physiological pH (7.4) may be substituted for DOTAP, including positively charged forms of cholesterol (ICE) in an SS-OP LNP formulation. The tested LNP formulations are shown below in Tables 7-12.
  • the overall flow rate was varied as shown in FIG. 13.
  • C57Bl/6 mice were dosed at 0.1mg/kg via intravenous injection, and lungs were imaged ex vivo 20 hours later. Shown is mean radiance of the lungs (photons/s/cm2/sr).
  • the highest signal for SS OP DOTAP formulation was found with 8 ml/minute flow rate for LNP mRNA encapsulation (FIG.13).
  • Table 13 compares the flow rate to particle size, zeta potential and encapsulation efficiency of the SS OP DOTAP formulation of Table 6A.
  • Table 13 Flow rate versus particle size, zeta potential and encapsulation efficiency
  • Example 12 DOPC and Cholesterol were not required for SS-OP DOTAP LNP mRNA delivery
  • Table 14 Flow rate versus particle size, zeta potential and encapsulation efficiency
  • Example 12 DOPC and Cholesterol were not required for SS-OP DOTAP LNP mRNA delivery
  • Table 14 SS-OP DOTAP formulations without DOPC and/or cholesterol
  • Example 13 Varying mRNA:lipid ratio showed differential activity [0579]
  • SS-OP DOTAP LNPs according to the formulation of Table 6A, and comprising the luciferase mRNA in an mRNA:lipid ratio (wt/wt) of 1:62, 1:45, and 1:30 were dosed intravenously in C57Bl/6 mice. Mice were dosed via intravenous injection at 1.5mg/kg, and lungs were imaged ex vivo 26 hours later.
  • FIG.15 shows that mRNA:lipid ratios of 1:30 through 1:62 were the best performing mRNA:lipid ratios, with 1:30 exhibiting the highest bioluminescence.
  • SS-OP DOTAP LNPs without DOPC and comprising firefly luciferase (Luc) mRNA at varied ratios were injected intravenously in C57Bl/6 mice at a dose of 1.5mg/kg. Lungs were imaged ex vivo 26 hours later. Shown is mean radiance of the lungs (photons/s/cm2/sr).
  • LNPs were not formed with an mRNA:lipid ratio of 1:5 (N.D. refers to not dosed).
  • Example 14 Varying PEGylated lipid percent showed differential activity [0582] To determine the effects of the percent PEGylated lipid on SS-OP DOTAP LNPs delivery of mRNA, LNPs were formulated per the ratios in Table 15 below with luciferase mRNA and were administered intravenously to C57Bl/6 mice in a dose of 1.5mg/kg. Lungs were imaged ex vivo 19 hours later. FIGS.17A and 17B show the mean radiance of the lungs (photons/s/cm 2 /sr).
  • the optimal PEGylated lipid range for SS-OP DOTAP LNPw was found to be 0- 3%, with 0.5% providing the best LNP delivery of mRNA (FIGS. 17A and 17B).
  • Table 15 shows the SS-OP DOTAP formulations with varied percentage of PEGylated lipid.
  • mice were dosed via intravenous injection and lungs were imaged ex vivo 21 hours later.
  • the LNP-mRNA dose was 1.5mg of mRNA per kg of animal mass for the 1.2% PEG and 0.1% PEG conditions.
  • the lipid to mRNA ratio was 63.
  • the mice were dosed at 0.2mg/kg.
  • Table 16 Low and no PEGylated lipid SS-OP DOTAP formulations
  • Example 15 Varying DOTAP percentage shows differential lung activity [0584] To determine the effects of varying DOTAP percentage on SS-OP DOTAP LNPs, SS-OP DOTAP LNPs were formulated with firefly luciferase (Luc) mRNA per the ratios in Table 17. C57Bl/6 mice were dosed via intravenous injection at 1.5mg/kg, and lungs were imaged ex vivo 19 hours later. FIG.19 shows the mean radiance of the lungs (photons/s/cm 2 /sr) relative to the percentage of DOTAP in the LNP.
  • Luc firefly luciferase
  • SS-OP DOTAP LNPs The most effective delivery of SS-OP DOTAP LNPs to the lung, among the formulas in Table 17, was 30% DOTAP. Minimum liver targeting was observed for LNPs have 20% or greater DOTAP; whereas strong liver signal was seen with 10% DOTAP (FIGS. 20A and 20B). Table 17 shows the SS-OP DOTAP formulations with varied DOTAP percentage.
  • Table 17 SS-OP DOTAP formulations with varied DOTAP percentage
  • Example 17 Delivery of LNP-mRNAs to the lung transfects alveolar epithelial cells [0585] To observe the cell types transfected by SS-OP DOTAP LNP per the formula of Table 6A, LNPs were formulated with Cre mRNA and administered to tomato fl/fl mice at 2.0 mg/kg (FIG.21A).
  • FIG.21B shows a PBS negative control.
  • Lungs were harvested 3 days later and processed via formalin fixation and paraffin embedding.4 ⁇ m sections were stained with: [0586] Anti-IGFBP2, a marker of AT1 alveolar epithelial lung cells, Anti-Prosurfactant Protein C (SPC) a marker of AT2 alveolar epithelial lung stem cells, Anti-tdTomato, and DAPI as a marker of DNA to identify cells.
  • SPC Anti-Prosurfactant Protein C
  • DAPI a marker of DNA to identify cells.
  • Cells positive for both SPC and tdTomato demonstrated that the LNP formulation successfully transfected lung AT2 alveolar epithelial stem cells.
  • Cells positive for both IGFBP2 and tdTomato demonstrated that the LNP formulation successfully transfected lung AT1 alveolar epithelial cells.
  • Example 18 TERT mRNA delivery in KO mice with SS-OP DOTAP [0587] To determine SS-OP DOTAP delivery of therapeutic mRNA as a disease treatment, SS-OP DOTAP LNPs encapsulating TERT mRNA were administered to a lung fibrosis model mouse. The timeline of the mouse lung fibrosis model lung and treatment are shown in FIG. 22. Lung fibrosis was induced in third generation (G3) TERT knock-out (KO) mice, which have telomere lengths that are similar to those of humans. Bleomycin was administered continuously via subcutaneously implanted osmotic minipump.
  • G3 third generation mice
  • TERT mRNA encapsulated in the SS-OP DOTAP LNP formulation of Table 6A was administered intravenously four times beginning on day 10, as shown. Relative to the control, which was firefly Luciferase mRNA, delivery of the TERT mRNA extended the survival rate of the mouse by 210% at the endpoint.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2022/022642 2021-03-31 2022-03-30 Compositions and methods for delivery of rna Ceased WO2022212576A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2022246851A AU2022246851A1 (en) 2021-03-31 2022-03-30 Compositions and methods for delivery of rna
CA3215112A CA3215112A1 (en) 2021-03-31 2022-03-30 Compositions and methods for delivery of rna
JP2023560598A JP2024513048A (ja) 2021-03-31 2022-03-30 Rnaの送達のための組成物及び方法
IL307319A IL307319A (en) 2021-03-31 2022-03-30 Compositions and methods for delivery of rna
EP22782138.6A EP4312942A4 (en) 2021-03-31 2022-03-30 Compositions and methods for delivery of RNA
CN202280026001.6A CN117396193A (zh) 2021-03-31 2022-03-30 用于递送rna的组合物和方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163169118P 2021-03-31 2021-03-31
US63/169,118 2021-03-31

Publications (1)

Publication Number Publication Date
WO2022212576A1 true WO2022212576A1 (en) 2022-10-06

Family

ID=83456716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/022642 Ceased WO2022212576A1 (en) 2021-03-31 2022-03-30 Compositions and methods for delivery of rna

Country Status (8)

Country Link
US (1) US20220347112A1 (cg-RX-API-DMAC10.html)
EP (1) EP4312942A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024513048A (cg-RX-API-DMAC10.html)
CN (1) CN117396193A (cg-RX-API-DMAC10.html)
AU (1) AU2022246851A1 (cg-RX-API-DMAC10.html)
CA (1) CA3215112A1 (cg-RX-API-DMAC10.html)
IL (1) IL307319A (cg-RX-API-DMAC10.html)
WO (1) WO2022212576A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024149229A1 (en) * 2023-01-10 2024-07-18 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticle compositions and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202509222A (zh) * 2023-05-08 2025-03-01 美商默沙東有限責任公司 編碼諾羅病毒vp1抗原之多核苷酸及其用途
WO2025049632A1 (en) * 2023-08-29 2025-03-06 Rejuvenation Technologies Inc. Compositions and methods for broad delivery of rna to tissue
WO2025255027A1 (en) * 2024-06-03 2025-12-11 Flagship Labs 114, Inc. Lipid nanoparticles for topical delivery
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026010842A1 (en) * 2024-07-01 2026-01-08 The Trustees Of The University Of Pennsylvania Use of lipid nanoparticle mrna for tert specific cancer immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180333457A1 (en) * 2017-05-16 2018-11-22 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF CODON-OPTIMIZED mRNA ENCODING CFTR
WO2019188867A1 (ja) * 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質
US20200215094A1 (en) * 2013-02-22 2020-07-09 The Board Of Trustees Of The Leland Stanford Junior University Compounds, compositions, methods, and kits relating to telomere extension

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2600800B (en) * 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CA3124524A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200215094A1 (en) * 2013-02-22 2020-07-09 The Board Of Trustees Of The Leland Stanford Junior University Compounds, compositions, methods, and kits relating to telomere extension
US20180333457A1 (en) * 2017-05-16 2018-11-22 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF CODON-OPTIMIZED mRNA ENCODING CFTR
WO2019188867A1 (ja) * 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4312942A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024149229A1 (en) * 2023-01-10 2024-07-18 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticle compositions and uses thereof
US20250090472A1 (en) * 2023-01-10 2025-03-20 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticle compositions and uses thereof

Also Published As

Publication number Publication date
CA3215112A1 (en) 2022-10-06
EP4312942A1 (en) 2024-02-07
AU2022246851A1 (en) 2023-10-12
JP2024513048A (ja) 2024-03-21
CN117396193A (zh) 2024-01-12
AU2022246851A9 (en) 2023-10-26
EP4312942A4 (en) 2025-03-19
US20220347112A1 (en) 2022-11-03
IL307319A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US20220347112A1 (en) Compositions and methods for delivery of rna
US12144895B2 (en) Stabilized formulations of lipid nanoparticles
US12357575B2 (en) Methods of making lipid nanoparticles
EP3595727B1 (en) Lipid nanoparticle formulation
US20210378980A1 (en) Preparation of lipid nanoparticles and methods of administration thereof
US20200069599A1 (en) Stabilized formulations of lipid nanoparticles
CN113939282A (zh) 制备脂质纳米颗粒的方法
WO2022147039A1 (en) Compositions and methods for delivery of rna
WO2020146344A1 (en) Composition and methods for treatment of primary ciliary dyskinesia
WO2026103877A1 (zh) 脂质化合物和脂质纳米颗粒组合物
HK40101750A (en) Compositions and methods for delivery of rna
WO2024112882A1 (en) Targeted delivery of gene editing constructs and methods of use thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3215112

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2022246851

Country of ref document: AU

Ref document number: AU2022246851

Country of ref document: AU

Ref document number: 307319

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 202280026001.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2023560598

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: P6002522/2023

Country of ref document: AE

ENP Entry into the national phase

Ref document number: 2022246851

Country of ref document: AU

Date of ref document: 20220330

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22782138

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202317073123

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2022782138

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022782138

Country of ref document: EP

Effective date: 20231031

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 523450793

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 523450793

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 523450793

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 523450793

Country of ref document: SA